CV - Kemerburgaz Üniversitesi

ÖZGEÇMİŞ VE ESERLER LİSTESİ
ÖZGEÇMİŞ
Adı Soyadı:
Mehmet Murat İnal
Doğum Tarihi:
18 Ocak 1970
Öğrenim Durumu:
Derece
Bölüm / Program
Üniversite
Yıl
Y.Lisans
Tıp Fakültesi
Hacettepe Üniversitesi
1996
Kadın Hastalıkları ve
SSK Ege Doğumevi ve Kadın
2001
Doğum
Hastalıkları Eğitim ve Araştırma
(İngilizce)
Tıpta Uzmanlık
Hastanesi
Doçentlik
Kadın Hastalıkları ve
Gazi Üniversitesi (Sınav Yeri)
2007
Doğum
Yan Dal Uzmanlık
Jinekolojik Onkoloji
2011
Cerrahisi
Doktora Tezi/S.Yeterlik Çalışması/Tıpta Uzmanlık Tezi Başlığı (özeti ekte)
ve
Danışman (lar)ı :
“Endometrial Ablasyon Sonrası Endometriumun Ofis Histeroskopi ile Alınan Biyopsilerle
Değerlendirilmesi ve Endometrial Ablasyonun Tedavi Edici Etkilerinin İncelenmesi”
(2001).
Tez Danışmanı: Dr Ahmet Seçkin Önoğlu
1
Görevler:
Görev Ünvanı
Görev Yeri
Yıl
Asistan Doktor
SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi
1997-2001
Uzman Doktor
Sağlık Bakanlığı Ege Doğumevi ve Kadın Hastalıkları
2001-2008
Eğitim ve Araştırma Hastanesi
Doçent Doktor
Antalya Medical Park Hastane Kompleksi
2010-2014
Antalya Medical Park Hastane Kompleksi
2014 -
(Bölüm Başkanı)
Profesör Doktor
İstanbul Kemerburgaz Üniversitesi Tıp Fakültesi
Yönetilen Doktora Tezleri/Sanatta Yeterlilik/Tıpta Uzmanlık Tez Çalışmaları:
1. Yıldırım, Y.,
“Renal Transplant Hastalarında Ovaryan Fonksiyon ve Fertilite”, SSK
Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi, 2003.
2. Karacaer, M., “Nöral Tüp Defektlerinde Faktör V (1691GA) Leiden ve Protrombin
20210GA Genetik Polimorfizminin Araştırılması”, SSK Ege Doğumevi ve Kadın
Hastalıkları Eğitim Hastanesi, 2004.
3. Şentaş, A., “Endometriozis Patogenezinde Anjiogenik Faktörlerden “Transforming
Growth Factor”ün Önemi”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim
Hastanesi, 2004.
4. Karaltı, M.O., “Nöral Tüp Defektlerinde 5,10-Metilentetrahidrofolat redüktaz
(MTHFR) Genetik Polimorfizminin Araştırılması”, SSK Ege Doğumevi ve Kadın
Hastalıkları Eğitim Hastanesi, 2004.
5. Naykı, C., “Erken Doğum Eylemi Tedavisinde Direkt Tokolitik Ajanlar ile
Hidrasyon-Sedasyon-Yatak
İstirahati
ve
Etkene
Yönelik
Tedavinin
Karşılaştırılması”, SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi,
2004.
6. Altındağ, M., “Epitelyal Over Tümörlerinde Thomsen-FriedenReich Antijenin
İmmünohistokimyasal Yöntemle Değerlendirilmesi”, SSK Ege Doğumevi ve Kadın
Hastalıkları Eğitim Hastanesi, 2005.
2
7. Uğurlu,
T.,
“Fetal
Kromozomal
Anomalilerin
QF-PCR
(Kantitatif
Floresan
Polimeraz Zincir Reaksiyonu) ile Tespiti ve Etkinliğin Amniosit Kültürleri ile
Karşılaştırılması”, SB Ege Doğumevi ve Kadın Hastalıkları Eğitim ve Araştırma
Hastanesi, 2007.
Projelerde Yaptığı Görevler:
1. “Implanon Uygulama ve Kabul Edilebilirlik Çok Merkezli Pilot Çalışması” Sağlık
Bakanlığı AÇSAP Derialtı Kontraseptif İmplant Projesi, Uygulayıcı, 2002.
2. “Medikal Abortus Çok Merkezli Çalışması” Dünya Sağlık Örgütü, “Gynuity Health
Projects”, Uygulayıcı, 2007.
İdari Görevler:
Yönetim Kurulu Üyeliği, Türk Jinekoloji ve Obstetrik Derneği, İzmir Şubesi, 2002-2004
Bilimsel Kuruluşlara Üyelikler:
1. Türk Jinekoloji ve Obstetrik Derneği
2. Türk Jinekolojik Onkoloji Derneği
3. European Society of Contraception (ESC)
4. European Society of Gynecological Oncology (ESGO)
5. International Gynecologic Cancer Society (IGCS)
ESERLER
A. Uluslararası hakemli dergilerde yayımlanan makaleler:
A1. Sadik, S., Onoglu, AS., M.M. Inal, Guler, A., Arici, A., Ispahi, C., “Experience in
Office Mini-hysteroscopy”, Gynecol Endoscopy, 11 (5): 251-256 (2002).
A2. Taskin, O., Onoglu, A., M. Inal, Turan, E., Sadik, S., Vardar, E., Postaci, H.,
Wheeler, JM., “Long-term Histopathologic and Morphologic Changes after Thermal
Endometrial Ablation”, J Am Assoc Gynecol Laparosc, 9 (2): 186-190 (2002).
A3. Taner, C., M. Inal, Basogul, O., Onoglu, A., Karanfil, C., Tinar, S., Ispahi, C.,
“Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus an
Oral Contraceptive in the Treatment of Hirsutism”, Gynecol Obstet Invest, 54 (2): 105108 (2002).
3
A4. Vardar, E., Maral, I., M. Inal, Ozguder, O., Tasli, F., Postaci, H., “Comparison of
Gram Stain and Pap Smear Procedures in the Diagnosis of Bacterial Vaginosis”, Infect Dis
Obstet Gynecol, 10 (4): 203-207 (2002).
A5. M.M. Inal, Ertopcu, K., Arici, A., Ozelmas, I., “The Effect of Oral versus Vaginal
Misoprostol on Cervical Dilatation in First-trimester Abortion: A Double-blind, Randomized
Study”, Eur J Contracept Reprod Health Care, 8 (4): 197-202 (2003).
A6. Tinar, S., Sehirali, S., M.M. Inal, Yildirim, Y., Celik, E., Yigit, S., “Adenosarcoma of
the Uterus: A Case Report”, MedGenMed (electronic resource): Medscape General
Medicine, 6 (1): 51 (2004).
A7. Yildirim, Y., M.M. Inal, Sanci, M., Sentas, A., Hanhan, M., “Uterine Sarcomas: A 10
Year Experience and A Review of the Literature”, Women’s Oncology Review, 4 (1): 7-12
(2004).
A8. M.M. Inal, Hanhan, M., Pilanci, B., Tinar, S., “Fallopian Tube Malignancies:
Experience of Social Security Agency Aegean Maternity Hospital”, Int J Gynecol Cancer,
14 (4): 595-599 (2004).
A9. M.M. Inal, Hanhan, M., Demir, OF., Polat, M., Tinar, S., “Experience of SSK (Social
Security Agency) Aegean Maternity Hospital on Choriocarcinomas”, Women’s Oncology
Review, 4 (3): 169-174 (2004).
A10. Sehirali, S., M.M. Inal, Ozsezgin, S., Sanci, M., Atli, O., Nayki, C., Yildirim, Y.,
Tinar S., “A Randomized Prospective Study of Comparison of Reservoir Ports versus
Conventional Vascular Access in Advanced-Stage Ovarian Carcinoma Cases Treated with
Chemotherapy”, Int J Gynecol Cancer, 15 (2): 228-232 (2005).
A11. Ertopcu, K., M.M. Inal, Ozelmas, I., “Demographic Analysis of Post-Abortive and
Interval-Administered Hormonal Contraceptive Methods”, Eur J Contracept Reprod Health
Care, 10 (1): 1-5 (2005).
A12. Yildirim, Y., Tinar, S., Yildirim, YK., M.M. Inal, “Comparison of Pituitary-Ovarian
Function in Patients Who Have Undergone Successful Renal Transplantation and Healthy
Women”, Fertil Steril, 83 (5): 1553-1556 (2005).
A13. Yildirim, Y., M.M. Inal, Tinar, S., “Reproductive and Obstetric Characteristics of
Adolescent Pregnancies in Turkish Women”, J Pediatr Adolesc Gynecol, 18 (4): 249-253
(2005).
4
A14. Yildirim, Y., M. Inal, Tinar S., “Necrotizing Fasciitis after Abdominal Hysterectomy:
A Report on Five Cases”, Arch Gynecol Obstet, 273 (2): 126-128 (2005).
A15. Sehirali, S., M.M. Inal, Yildirim, Y., Balim, Z., Kosova, B., Karamizrak, T., Sanci,
M., Topcuoglu, N., Tinar, S., “Prothrombin G20210A Mutation in Cases with Recurrent
Miscarriage: A Study of the Mediterranean Population”, Arch Gynecol Obstet, 273 (3):
170-173 (2005).
A16. Yildirim, Y., M.M. Inal, Sanci, M., Yildirim, YK., Mit, T., Polat, M., Tinar, S.,
“Development of Uterine Sarcoma after Tamoxifen Treatment for Breast Cancer: Report
of Four Cases”, Int J Gynecol Cancer, 15 (6): 1239-1242 (2005).
A17. M.M. Inal, Ertopcu, K., Ozelmas, I., “The Evaluation of 318 Intrauterine Pregnancy
Cases with An Intrauterine Device”, Eur J Contracept Reprod Health Care, 10 (4): 266271 (2005).
A18. M.M. Inal, Incebiyik, A., Sanci, M., Yildirim, Y., Polat, M., Pilanci, B., Nayki, C.,
Camuzcuoglu, H., “Ovarian Cysts in Tamoxifen-Treated Women with Breast Cancer”, Eur
J Obstet Gynecol Reprod Biol, 120 (1): 104-106 (2005).
A19. M.M. Inal, Yildirim, Y., Taner, CE., “Comparison of the Clinical Efficacy of
Flutamide and Spironolactone plus Diane 35 in the Treatment of Idiopathic Hirsutism: A
Randomized Controlled Study”, Fertil Steril, 84 (6): 1693-1697 (2005).
A20. Hanhan, M., M.M. Inal, Oztekin, D., Dicle, N., Ozsaran, Z., Tinar, S., “Prognosis of
Early Invasive and Locally Advanced (stage I, II) Uterine Cervical Adenocarcinomas”,
Cancer Therapy, vol 4: 263-270 (electronically published) (2006).
A21. M. Inal, Yildirim, Y., Incebiyik, A., Sanci, M., Ispahi, C., “Diagnostic Accuracy of
Sonohysterography in the Evaluation of Uterine Cavities in Tamoxifen Administered
Asymptomatic Postmenopausal Breast Cancer Patients with Endometrial Thickness ≥5
mm”, Gynecol Surg, 3 (4): 271-274 (2006).
A22. M.M. Inal, Yildirim, Y., Ertopcu, K., Ozelmas, I., “The Predictors of Retained
Products of Conception Following First-trimester Pregnancy Termination with Manual
Vacuum Aspiration”, Eur J Contracept Reprod Health Care, 11 (2): 98-103 (2006).
A23. Onoglu, AS., Taskın, O., M. Inal, Sadik S., “Comparison of the Long Term
Histopathologic and Morphologic Changes after Endometrial Roller-ball Ablation and
Resection: A Prospective Randomized Trial”, The J Min Inv Gyn, 14 (1): 39-42 (2007).
5
A24. M.M. Inal, Kose, S., Yildirim, Y., Ozdemir, Y., Toz, E., Ertopcu, K., Ozelmas, I.,
Tinar, S., “The Relationship Between HPV Infection and Cervical Intraepithelial Neoplasia
(CIN) in Turkish Women”, Int J Gynecol Cancer, 17 (6): 1266–1270 (2007).
A25. M.M. Inal, Yildirim Y., Ertopcu K., Avci ME., Ozelmas I., Tinar S., “Effect of the
subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal
parameters (three years follow-up)”, Eur J Contracept Reprod Health Care, 13 (3): 23842 (2008).
A26. Yildirim Y., Gultekin E., Avci ME., M.M. Inal, Yunus S., Tinar S., “Cardiac safety
profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative
doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer”, Int J
Gynecol Cancer, 18 (2): 223-7 (2008).
A27. Onay H., Ugurlu T., Aykut A., Pehlivan S., M. Inal, Tinar S., Ozkinay C., Ozkinay
F., “Rapid prenatal diagnosis of common aneuploidies in amniotic fluid using quantitative
fluorescent polymerase chain reaction”, Gynecol Obstet Invest, 66 (2): 104-10 (2008).
A28. Kose S., Ersan G., Sender SS., Devrim I., M.M. Inal., “A prevalence study of
Chlamydia infections in Turkish population”, Braz J Infect Dis, 17 (1): 114-5 (2013).
B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings)
basılan bildiriler :
B1. C. Taner, Inal M., O. Basogul, A. Onoglu, C. Karanfil, S. Tinar, C. Ispahi,
“Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus An
Oral Contraceptive in the Treatment of Hirsutism”, The Second World Congress on
Controversies in Obstetrics Gynecology & Infertility, Paris, France, September 6-9, 2001.
B2. K. Ertopcu, G. Undar, Z. Benli, H. Unluoglu, S. Coskun, Inal M., I. Ozelmas,
“Demographic Analysis of Postabortive and Interval Hormonal Contraceptive Method
Applicated Cases”. The 7th Congress of the European Society of Contraception, Genova,
Italy, April 2002.
B3. K. Ertopçu, G. Undar, Inal M., S. Tinar, I. Ozelmas, “Evaluation of 100 cases who
have Pregnancies with IUDs and Want Their Pregnancies to Continue”, The 7th Congress
of the European Society of Contraception, Genova, Italy, April 2002.
B4. S. Sehirali, Z. Balim, Inal M.M., B. Kosova, T. Karamizrak, N. Topcuoglu, M. Sanci,
S. Tinar, “The Evaluation of Factor V Leiden and Prothrombin 20210A in Preeclampsia
6
Cases”, 5th Congress of the European Society of Gynecology, Rhodes, Greece, October
9-11, 2003.
B5. Z. Balim, S. Sehirali, Inal M.M., B. Kosova, O. Atli, N. Topcuoglu, T. Karamizrak, S.
Tinar, “Evaluation of Factor V Leiden and Prothrombin 20210A Mutations in Cases with
Diagnosis of Habitual Abortus”, 5th Congress of the European Society of Gynecology,
Rhodes, Greece, October 9-11, 2003.
B6. A. Incebiyik, Inal M.M., M. Sanci, H. Camuzcuoglu, B. Pilanci, “Comparison of
Transvaginal Sonohysterography and Office Hysteroscopy in Evaluation of Uterine
Cavities of Tamoxifen Administered Postmenopausal Cases with Breast Cancer”. 5th
Congress of the European Society of Gynecology, Rhodes, Greece, October 9-11, 2003.
B7. K. Ertopcu, Inal M.M., A. Donmez, I. Ozelmas, S. Tinar, “Interval versus
Postabortive Counseling: Demographic Characteristics and Effect of Reproductive Desire
on Method Selection (14332 cases)”, The 8th Congress of the European Society of
Contraception, Edinburgh, Britain, June 2004.
B8. Inal M.M., K. Ertopcu, M. Karacaer, M. Polat, S. Yetkin, I. Bicer, I. Ozelmas, S.
Tinar, “Effect of Subdermal Contraceptive Implant (Implanon®) on Biochemical Serum
Parameters”, The 8th Congress of the European Society of Contraception, Edinburgh,
Britain, June 2004.
B9. Y. Yakut, B. Dilbaz, H. Aktun, M. Sezgen, C. Simsek, Z. Vural, S. Yılmaz, Inal M., G.
Atılgan, D. Aksit, A. Koseli, R. Kose – Ministry of Health, Implanon Study Group, “One
Year Follow-up of Patients on Implanon® for Contraception: A Multicentric Prospective
Study”, The 8th Congress of the European Society of Contraception, Edinburgh, Britain,
June 2004.
B10. K. Ertopcu, Inal M.M., A. Donmez, I. Ergin, S. Yetkin, S. Vardar, O. Bicer, I.
Ozelmas, “Effect of Contraception on Depression: Comparison of Edinburgh and Beck
Depression Scales”, The 8th Congress of the European Society of Contraception,
Edinburgh, Britain, June 2004.
B11. Inal M.M., K. Ertopcu, C. Nayki, U. Nayki, A. Donmez, S. Vardar, I. Ozelmas, S.
Tinar,
“Effect
of
Subdermal
Contraceptive
Implant
(Implanon®)
on
Hormonal
Parameters”, The 8th Congress of the European Society of Contraception, Edinburgh,
Britain, June 2004.
7
B12. Inal M.M., A. Incebiyik, N. Dicle, Y. Yildirim, M. Polat, A. Uysal, M. Altındag, M.
Sanci, “Steroid Hormone Receptor Evaluation in the Endometria of the Tamoxifen
Administered Cases with Breast Cancer”, 11th World Congress of Gynecological
Endocrinology, Florence, Italy, February 2005.
B13. S. Ozsezgin-Ocek, S. Sehirali, Inal M.M., M. Sanci, C. Ispahi, “Epidural Ports in
Relief of Gynecological Cancer Pain”, 11th World Congress on Pain, IASP, Sydney,
Australia, August 2005.
B14. Inal M.M., “Genetic Evaluation in Habitual Abortions”. Proceedings of the 8th
International
Conference
on
“Emerging
Technologies
in
Drug
and
Gene-based
Therapeutics”, p169, Crete, Greece, September 2005.
B15. K. Ertopcu, Inal M.M., Z. Ozenc, A. Donmez, G. Yildirimkaya, I. Ozelmas, S. Tinar,
“Contraception Again with IUD after IUD Dislocation and IUD+Pregnancy (Evaluation of
6412 cases)”, The 9th Congress of the European Society of Contraception, İstanbul,
Turkey, May 2006.
B16. K. Ertopcu, Inal M.M., N. Kokturk, I. Ozelmas, S. Tinar, “Continuity of Implanon
Usage after Three Years of Use”, The 9th Congress of the European Society of
Contraception, İstanbul, Turkey, May 2006.
B17. K. Ertopcu, Inal M.M., Z. Ozenc, A. Donmez, F. Ozdemir, I. Ozelmas, S. Tınar,
“Evaluation of Placental Retentions after 8536 Uterine Evacuations”, The 9th Congress of
the European Society of Contraception, İstanbul, Turkey, May 2006.
B18. Inal M.M., S. Kose, K. Ertopcu, M.E. Avci, A. Donmez, I. Ergin, I. Ozelmas, S.
Tinar, “Vaginal Infections in Family Planning Regular Visitors”, The 9th Congress of the
European Society of Contraception, İstanbul, Turkey, May 2006.
B19. Inal M.M., S. Kose, K. Ertopcu, F. Demirci, A. Donmez, D. Oztekin, I. Ozelmas, S.
Tinar, “Chlamydia: Prevalance Study of Turkish Population”, The 9th Congress of the
European Society of Contraception, İstanbul, Turkey, May 2006.
B20. Inal M.M., S. Kose, Y. Yildirim, Y. Ozdemir, E. Toz, K. Ertopcu, I. Ozelmas, S.
Tinar, “The Relationship between HPV Infection and Cervical Intraepithelial Neoplasia
(CIN) in Turkish Women”, 18th FIGO World Congress, Kuala Lumpur, Malaysia,
November, 2006.
8
C. Yazılan uluslararası kitaplar veya kitaplarda bölümler:
D. Ulusal hakemli dergilerde yayımlanan makaleler:
D1. Sancı, M., M.M. İnal, “60 Yaş Üzeri Kadınlarda Jinekolojik Operasyonlar”, Geriatri, 2
(3): 127-131 (1999).
D2. Basogul, N., Sanci, M., Tinar, S., Basogul, O., M.M. Inal, “The Importance of
Doppler Ultrasonography, Ultrasonographic Morphologic Scores and Ca-125 in Differential
Diagnosis of Pelvic Masses”, Gynecol Obstet Reprod Med, 6 (3): 201-204 (2000).
D3. Hanhan, M., Vardar, E., Keleş, R., Özbakkaloğlu, A., M.M. İnal, “Evre I İnvaziv
Serviks Karsinomları: SSK Ege Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi
Deneyimi”, Ege Tıp Dergisi, 39 (1): 51-55 (2000).
D4. Maral, İ., M. İnal, Koru, E., Başoğul, N., Başoğul, Ö., “Gebelik ve Adneksial Torsiyon
(Olgu Sunumu)”, Ege Tıp Dergisi, 39 (3): 221 – 223 (2000).
D5. Sancı, M., M.M. İnal, Güler, A., Özgüder, T., Arıcı, A., İspahi, Ç., Tınar, Ş.,
“Refrakter Hiperemezis Gravidarum’un Tedavisinde Oral Metilprednisolon’un Yeri”, Klinik
Bilimler ve Doktor, 8 (3): 367-370 (2002).
D6. M.M. İnal, Sancı, M., Güler, A., Özgüder, T., Arıcı, A., İspahi, Ç., Tınar, Ş.,
“Endometrial Ablasyon Sonrası Gebelik: Olgu Sunumu”, Klinik Bilimler ve Doktor, 8 (3):
398-400 (2002).
D7. Sancı, M., Taner, CE., M.M. İnal, Pilancı, MB., Arıöz, DT., Uysal, A., “Sezeryan
Sonrası Ağrı Kontrolünde İnsizyon Öncesi Lokal Anestezinin Etkisi”, Klinik Bilimler ve
Doktor, 8 (3): 379-382 (2002).
D8. Oner, RS., Sanci, M., Albayram, F., M.M. Inal, Maral, I., “Heterozygous
Achondroplasia: Prenatal Diagnosis”, Gynecol Obstet Reprod Med, 9 (1): 44-45 (2003).
D9. M.M.İnal, Aydar, GU., Pilancı, MB., İncebıyık, A., Sancı, M., Tınar, Ş., “Gebelik ve
Adneksial
Torsiyon (Olgu Sunumu)”, MN Klinik Bilimler ve Doktor, 9 (1): 103-105
(2003).
9
D10. Pilancı, MB., İncebıyık, A., Camuzcuoğlu, H., M.M. İnal, Tınar, Ş., İspahi, Ç.,
“Müllerian Agenezis: 8 Olgu, Sınıflama ve Yaklaşım”, Klinik Bilimler ve Doktor, 10 (5):
600-604 (2004).
D11. Karakoç, MK., Gür, EB., Sancı, M., M.M. İnal, Şahin, E., Çelik, E., Kızılyar, A.,
İmren, A., “Gestasyonel DM’ta Fetal ve Maternal Sonuçlar: OGTT’de Tek Değer
Yüksekliğinin İrdelenmesi”, Klinik Bilimler ve Doktor, 11 (1): 87-92 (2005).
D12. Sancı, M., Gür, EB., M.M. İnal, Sekü, İ., Şahin, E., Kurtulmuş, S., Boyacıoğlu, H.,
Kızılyar, A., “Gestasyonel DM Taramasında 50 gr Glukoz Tarama Testinin Etkinliği”, Klinik
Bilimler ve Doktor, 11 (1): 83-86 (2005).
D13. M.M. İnal, “Bariyer Kontraseptif Yöntemler”, Türkiye Klinikleri Jinekoloji Obstetrik,
2 (22): 41-50 (2006).
D14. M. İnal, Yıldırım, Y., Ertopcu, K., Özelmas, İ., Tınar, Ş., “Ege Doğumevi ve Kadın
Hastalıkları Eğitim ve Araştırma Hastanesi Aile Planlaması Bölümü’ne 2001-2005 yılları
Arasında Başvuran Perimenopozal Kadınlar Tarafından Kullanılan Kontraseptif Yöntemler”,
Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, 7 (2): 013-016 (2006).
D15. Naykı, C., M. İnal, Yıldırım, Y., Tınar, Ş. “Preterm Doğum Eyleminin Tedavisinde
Nifedipin ile Hidrasyon+Sedasyon’un Karşılaştırılması: Prospektif Klinik Bir Çalışma”,
Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, 8 (1): 23-26 (2007).
D16. Balsak, D., M. İnal, Yıldırım Y., Öner, RS., Tınar, Ş., “Rüptüre Olmamış Kornual
Gebeliğin
Intravenöz
Methotrexate
ile
Başarılı
Tedavisi:
Olgu
Sunumu”,
İnönü
Üniversitesi Tıp Fakültesi Dergisi, 14 (1): 65-67 (2007).
D17. Yıldırım, Y., Balsak, D., M. İnal, Tınar, Ş., “Overin Malign Mikst Mullerian Tümör’ü:
Klinikopatolojik Özellikler, Tedavi ve Prognoz”, İnönü Üniversitesi Tıp Fakültesi Dergisi,
14 (1): 37-40 (2007).
D18. Sentas, A., M. Inal, Sanci, M., Yildirim, Y., Inan, S., Vatansever, S., Dicle, N.,
“Immunohistochemical Evaluation of TGF-β Isoforms in Cases with Ovarian Endometriosis
and Follicular Cyst”, Gynecol Obstet Reprod Med (GORM), 13 (1): 34-37 (2007).
D19. Karalti, O., M. Inal, Yildirim, Y., Çoker, I., Tınar, Ş., “The relationship between
maternal
5,10-methylenetetrahydrofolate reductase C677T polymorphism and
the
development of neural tube defects: a 5-year study in Aegean Obstetrics and Gynecology
Training and Research Hospital”, Turkiye Klinikleri J Gynecol Obst, 17 (5): 337-41
(2007).
10
D20. Yildirim, Y., Sonmez, S., Toz, E., M. Inal, Aykas, A., Uslu, A., “Solid Organ
(Kidney, Liver, Pancreas-Kidney, Heart, Lung and Heart-lung) Transplantations and
Pregnancy”, Marmara Medical Journal, 21 (1); 079-088 (2008).
E. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:
E1. İ. Maral, J. Duran, E. Koru, İnal, M.M., “Gebelik + Adneksial Torsiyon”, Perinatoloji
Kongresi, Antalya, 10-13 Mayıs 1998.
E2. İ. Maral, Y. Özgenç, İnal, M.M., “Gebelik + Metastatik Ca”, Perinatoloji Kongresi,
Antalya, 10-13 Mayıs 1998.
E3. İ. Maral, RS. Öner, H. Kanıt, İnal, M.M., “Heterozigos Akondroplazi”, Perinatoloji
Kongresi, Antalya, 10-13 Mayıs 1998.
E4. İ. Maral, RS. Öner, H. Kanıt, İnal, M.M., “Prenatal USG Teşhis: Fetal Cystic
Adenomatoid Malformation (CCAM)”, Perinatoloji Kongresi, Antalya, 10-13 Mayıs 1998.
E5. K. Ertopçu, İ. Özelmas, A. Kaçar, O. Alparslan, İnal, M.M., A. Özkutucu, MA. Şanlı,
A. Arıcı, “İntraabdominal Rahimiçi Araçların Laparoskopik Çıkarılması (42 Olgunun
Değerlendirilmesi)”, 1.Ulusal Aile Planlaması Kongresi, Ankara, 14-17 Nisan 1999.
E6. AS. Önoğlu, S. Sadık, E. Turan, O. Alparslan, İnal, M.M., Ç. İspahi, S. Menteşoğlu,
“Ofis Laparoskopinin İnfertil Olgularda Rutin Kullanımı”, Türk-Alman Jinekoloji Derneği 3.
Jinekoloji ve Obstetrik Kongresi, Antalya, 19-23 Mayıs 1999.
E7. CE. Taner, Ö. Başoğul, İnal, M.M., AS. Önoğlu, S. Öztamur, Ş. Tınar, “Anovulatuar
Polikistik Overli İnfertil Kadınlarda Düşük Doz Protokol ile uFSH ve rFSH Uygulama
Sonuçları”, 21.Yüzyılda Üreme Sağlığı ve Endoskopik Cerrahi Kongresi, Kuşadası, Aydın,
14-17 Eylül 2000.
E8. N. Başoğul, M. Sancı, Ö. Başoğul, Ş. Tınar, İnal, M.M., C. Çankaya, “İzole
Segmental Jejunal Dilatasyon Nedeniyle Antenatal İntestinal Obstruksiyon Bulgusu: Olgu
Sunumu”, 21.Yüzyılda Üreme Sağlığı ve Endoskopik Cerrahi Kongresi, Kuşadası, Aydın,
14-17 Eylül 2000.
E9. C. Karanfil, CE. Taner, E. Balık, İnal, M.M., “Genital Prolapsus Tedavisinde
Histerektomisiz Cerrahi Yaklaşım”, Türk-Alman Jinekoloji Derneği 4. Kongresi, Antalya,
30 Mayıs – 3 Haziran 2001.
11
E10. M. Sancı, İnal, M.M., A. Güler, Ç. İspahi, Ş. Tınar, “Refrakter Hiperemezis
Gravidarum’un Tedavisinde Oral Metilprednisolon’un Yeri”, 3.Ulusal Jinekoloji ve Obstetrik
Kongresi, İstanbul, 13-16 Eylül 2001.
E11. İnal, M.M., M. Sancı, A. Güler, Ç. İspahi, Ş. Tınar, “Pregnancy After Endometrial
Ablation: A Case Report”, 3.Ulusal Jinekoloji ve Obstetrik Kongresi, İstanbul, 13-16 Eylül
2001.
E12.
S.
Sadık,
AS.
Önoğlu,
İnal,
M.M.,
Ç.
İspahi,
“Ofis
Minihisteroskopi
Deneyimlerimiz”, 3.Ulusal Jinekoloji ve Obstetrik Kongresi, İstanbul, 13-16 Eylül 2001.
E13. M. Hanhan, R. Keleş, A. Güler, İnal, M.M., S. Sayhan, Ş. Tınar, “Uterusta Sınırlı
Pozitif Peritoneal Sitolojili Endometrium Kanserlerinde Yaklaşım”, 8.Ulusal Jinekolojik
Onkoloji Kongresi, Antalya, 1-5 Mayıs 2002.
E14. M. Hanhan, R. Keleş, İnal, M.M., Ş. Tınar, “Borderline Over Tümörleri”, 8.Ulusal
Jinekolojik Onkoloji Kongresi, Antalya, 1-5 Mayıs 2002.
E15. İnal, M.M., M. Hanhan, ÖF. Demir, Ş. Tınar, “Koriokarsinomlarda SSK Ege
Doğumevi ve Kadın Hastalıkları Eğitim Hastanesi Deneyimi”, 8.Ulusal Jinekolojik Onkoloji
Kongresi, Antalya, 1-5 Mayıs 2002.
E16. AS. Önoğlu, S. Sadık, A. Güler, O. Alparslan, İ. Akın, İnal, M.M., S. Şehirali, İ.
Sekü, Y. Yıldırım, “İnfertil Hastalarda Ofis Laparoskopi”, Güncel İnfertilite ve Yardımcı
Üreme Teknikleri Sempozyumu, İzmir, 24-27 Nisan 2003.
E17. S. Şehirali, S. Özsezgin, İnal, M.M., Ö. Atlı, Y. Yıldırım, C. Naykı, M. Sancı, Ş.
Tınar, “Kemoterapi Alan İleri Evre Over Kanserli Hastalarda Rezervuarlı Port Kullanımı ile
Konvansiyonel Damar Yolu Kullanımının Randomize Prospektif Çalışması”, 5.Türk-Alman
Jinekoloji Derneği ve 2. Reproductive Medicine Tartışmalı Konular ve Çözümler Ortak
Kongresi, Antalya, 16-20 Mayıs 2003.
E18. K. Ertopçu, BK. Saydam, İnal M.M., A. Dönmez, İ. Ergin, Ş. Vardar, S. Yetkin, İ.
Özelmas, “Danışmanlık ve Memnuniyet”, 4.Uluslararası Üreme Sağlığı ve Aile Planlaması
Kongresi, Ankara, 20-23 Nisan 2005.
E19. K. Ertopçu, İnal M.M., Z. Özenç, A. Dönmez, A. Turpçulu, İ. Özelmas, Ş. Tınar,
“Aylık Enjektabl Kontraseptiflerin 5 Yıllık Takibi”, 4.Uluslararası Üreme Sağlığı ve Aile
Planlaması Kongresi, Ankara, 20-23 Nisan 2005.
12
E20. Z. Özenç, İnal M.M., NS. Deniz, A. Dönmez, K. Ertopçu, İ. Özelmas, Ş. Tınar,
“Intern
Doktorların
Aile
Planlamasıyla
İlgili
Teorik
Bilgilerinin
Değerlendirilmesi”,
4.Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, Ankara, 20-23 Nisan 2005.
E21. Inal, M., Y. Yildirim, A. Incebiyik, M. Sanci, C. Ispahi, “Diagnostic Accuracy of
Sonohysterography in the Evaluation of Uterine Cavities in Tamoxifen Administered
Asymptomatic Postmenopausal Breast Cancer Patients with Endometrial Thickness ≥5
mm”, 10. Ulusal Jinekolojik Onkoloji Kongresi, Özet Kitabı, 38, Antalya, 2006.
E22. İnal, M.M., M. Altındağ, M. Sancı, S. İnan, K. Özbilgin, N. Dicle, S. Sayhan, Y.
Yıldırım,
C.
Ispahi,
“Over
Tümörlerinde
Thomsen-Friedenreich
Antijeni’nin
İmmunohistokimyasal Olarak İncelenmesi”, 10. Ulusal Jinekolojik Onkoloji Kongresi, Özet
Kitabı, 72, Antalya, 2006.
E23. D. Balsak, Inal, M.M., Y. Yildirim, RS. Oner, S. Tinar, “Conservative Treatment of
Unruptured Cornual Pregnancy Using Double-dose Intravenous Methotrexate: A Case
Report”, Türk Jinekoloji ve Obstetrik Derneği Kongresi, Uzmanlık Sonrası Eğitim ve
Güncel Gelişmeler Dergisi Kongre Özel Sayısı, 137, Antalya, 2006.
E24. A. Sentas, Inal, M., M. Sanci, Y. Yildirim, S. Inan, S. Vatansever, N. Dicle,
“Immunohistochemical Evaluation of TGF-β isoforms in Cases with Ovarian Endometriosis
and Follicular Cyst”, 2. Ulusal Üreme Endokrinolojisi ve İnfertilite Kongresi (TSRM2006),
Kongre Özet Kitabı, 213, Antalya, 2006.
F. Uluslararası kitap veya kitaplarda bölümlerin çevirisi:
F1. Inal M.M. “Pelvik Cerrahi’nin Psikolojik Yönleri”, In: TeLinde’s Operative Gynecology,
ed. Rock JA and Jones HW, Lippincott Williams & Wilkins; 9.Basım Türkçe Çevirisi ed.
Tavmergen, E., s23-40, Güven Kitabevi, İzmir, 2005.
F2. Inal M.M. “Jinekoloji’de Lazer Uygulaması”, In: TeLinde’s Operative Gynecology, ed.
Rock JA and Jones HW, Lippincott Williams & Wilkins; 9.Basım Türkçe Çevirisi ed.
Tavmergen, E., s303-330, Güven Kitabevi, İzmir, 2005.
F3. Inal M.M. “Meme Hastalıkları: Benign ve Malign”
In: TeLinde’s Operative
Gynecology, ed. Rock JA and Jones HW, Lippincott Williams & Wilkins; 9.Basım Türkçe
Çevirisi ed. Tavmergen, E., s303-330, Güven Kitabevi, İzmir, 2005.
13
G. Uluslararası bilimsel toplantılarda aldığı görevler:
G1. Organization Committee Member. 9th Congress of the European Society of
Contraception, Istanbul ,Turkey, May 2006.
G2. Trainee Committee Member. 14th European Meeting and Exchange Programme of
Trainees in Obstetrics and Gynecology. ENTOG (European Network of Trainees in
Obstetrics and Gynecology), Ljubljana, Slovenia, Nov 2004. (Davetiye)
H. Uluslararası bilimsel toplantılara katılımlar:
H1. The 7th Congress of the European Society of Contraception, Genova, Italy, April 1013, 2002.
H2. The 5th Congress of the European Society of Gynecology, Rhodes, Greece, October
9-11, 2003.
H3. The 8th International Conference “Emerging Technologies in Drug and Gene-based
Therapeutics”, Crete, Greece, September 3-10, 2005.
H4. The 9th Congress of the European Society of Contraception, Istanbul, Turkey, 3-6
May, 2006.
H5. MSD Speaker’s Forum; Leading the Way for Prevention of Cervical Cancer and
Beyond, Prag, Chech Republic, 29 February-2 March, 2008.
H6. 16th International Meeting of the European Society of Gynaecological Oncology
(ESGO) in Belgrade, Serbia October 11 - 14, 2009.
I. Uluslararası bilimsel toplantılarda konuşmalar:
I1. Inal M.M., “Genetic Evaluation in Habitual Abortions”. Proceedings of the 8th
International
Conference
on
“Emerging
Technologies
in
Drug
and
Gene-based
Therapeutics”, p169, Crete, Greece, September 2005.
14
I2. Inal M.M., “Sterilisation”, Meet the Expert Sessions. 9th Congress of the European
Society of Contraception, Istanbul, Turkey, May 2006.
I3. Inal M.M., “Contraception again with IUD after IUD dislocation and IUD+pregnancy
(evaluation of 6412 cases), Free Communication, 9th Congress of the European Society
of Contraception, Istanbul, Turkey, May 2006.
J.
Makale
Eleştirmenliği
(Reviewer)
Yaptığı
Uluslararası
Dergiler
ve
Eleştirmenliğini Yaptığı Makaleler:
J1. Placenta, “Manufacture of a Cell-Free Amnion Matrix Scaffold That Supports Amnion
Cell Outgrowth in vitro”, (PL-05-00099), 2005.
J2. Placenta, “15-Deoxy-Δ12,14-Prostaglandin J2 and Triglitazone Regulation of Release
of Phospholipid Metabolism, Inflammatory Cytokines and Proteases from Human
Gestational Tissues”, (PL-05-90114), 2005.
J3. Placenta, “Functional and Molecular Expression of AQP9 Channel and UT-A
Transporter in Normal and Preeclamptic Human Placenta”, (PL-05-90083), 2005.
J4. Placenta, “Cytotoxic Effect of Zinc-Citrate Compound on Choriocarcinoma Cell line”,
(PL-05-90071), 2005.
J5. Placenta, “Expression of Kallikrein, Bradykinin B2 Receptor and Endothelial Nitric
Oxide Synthase in Placenta in Normal Gestation, Preeclampsia and Placenta Accreta”,
(PL-05-90018), 2005.
J6. Placenta, “Purinergic Receptor Expression and Activation in First Trimester and Term
Human Placenta”, (PL-06-90008), 2006.
J7. Placenta, “Human Placenta: A Model for Biomonitoring of Lead and its Association
with Preterm Delivery Through the Modulation of Oxidant/Antioxidant Status”, (PL-0690049), 2006.
J8. Placenta, “Tumor Necrosis Factor – Alpha Converting Enzyme in the Human Placenta
Throughout Gestation”, (PL-06-90091), 2006.
J9. Fertil Steril,
“Outcome
of
Preimplantation
Genetic
Diagnosis in
Reciprocal
Translocations”, (F&S2341), 2006.
15
J10. Placenta, “Reference Weights for Placentas Delivered before the 28th Week of
Gestation”, (PL-07-90004), 2007.
J11. Placenta, “Imprinting and Promoter Usage of Insulin-like Growth Factor II in Twin
Discordant Placentae”, (PL-07-90045), 2007.
J12. Placenta, “Placental anti-oxidant gene polymorphisms, enzyme activity, and
oxidative stress in preeclampsia”, (PL-07-90091), 2007.
J13. Fertil Steril, “Immunocontraceptive Properties of Recombinant Sperm Protein DE:
Implications for the Development of Novel Contraceptives”, (F&S2624), 2007.
J14. Fertil Steril, “Estrogen Receptor Alpha Gene Polymorphisms are Associated with
Idiopathic Premature Ovarian Failure”, (F&S3366), 2007.
J15. Fertil Steril, “Protective effects of amlodipine on ischemia/reperfusion injury of rat
ovary: biochemical and histopathologic evaluation”, (F&S4009), 2007.
J16. Placenta, “Induction of trophoblast cell fusion by a protein tyrosine phosphatase
inhibitör”, (PL-07-90099), 2007.
J17. Fertil Steril, “Intercoat Gel (Oxiplex): Efficacy, safety and tissue response in a
laparoscopic mouse model”, (F&S5668), 2008.
J18. Fertil Steril, “The Contribution of Rescue Spontaneous Maturation in Controlled
Ovarian Stimulation Cycles of Poor Responder Patients”, (F&S5775), 2008.
J19. Placenta, “Cyclooxygenase-2 derived PGE2 and PGI2 play an important role via
EP2 and PPARδ receptors in early steps of oil induced decidualization in mice”, (PL-0890005), 2008.
J20. Placenta, “Leptin Stimulates System A Amino Acid Transport: Evidence of a Direct
Effect on Human Placental Function”, (PL-08-90002), 2008.
J21. Placenta, “Placental weight in mosaic trisomy pregnancies”, (PL-08-90046), 2008.
J22. Placenta, “Conditioned medium from human decidual stromal cells has a
concentration-dependent effect on trophoblast cell invasion”, (PL-08-90068), 2008.
J23. Placenta, “Dietary protein and energy during gestation affects circulating indicators
of placental function and fetal development in heifers”, (PL-08-90143), 2008.
16
J24. Fertil Steril, “Variations in folate pathway genes are associated with unexplained
female infertility”, (F&S6530), 2009.
J25. Fertil Steril, “Evidence of prokineticin dysregulation in Fallopian tube from women
with ectopic pregnancy”, (F&S7778), 2009.
J26. Gyn Oncology, “The association between metabolic abnormality and endometrial
cancer: a large case-control study in China”, (GYN-09-1050), 2009.
J27. Gyn Oncology, “A global review of age-specific and overall prevalence of cervical
precancerous lesions”, (GYN-09-1135), 2009.
J28. Placenta, “CFTR may modulate AQP9 functionality in preeclamptic placentas”, (PL09-90021), 2009.
J29. Placenta, “High Saturated Fat Diet Induces Gestational Diabetes and Placental
Vasculopathy in C57BL/6 Mice”, (PL-09-90065), 2009.
J30.
Placenta,
“Dexamethasone
stimulates
placental
system
A
transport
and
trophoblast differentiation in term villous explants”, (PL-09-90113), 2009.
J31. Placenta, “Proteases and sFlt-1 release in the human placenta”, (PL-10-90003),
2010.
J32. Fertil Steril, “Increased viability of endometrial cells by in vitro treatment with di(2-ethylhexyl) phthalate”, (F&S8839), 2010.
K. Ulusal bilimsel toplantılarda aldığı görevler:
K1. İnal M.M., “Adolesan Jinekolojisi – Vajinal Enfeksiyonlar” (Konuşma): İzmir Türk
Jinekoloji ve Obstetrik Derneği Eğitim Toplantısı, İzmir, 18 Ocak 2002.
K2. İnal M.M., “Ciltaltı İmplant Uygulamaları” (Konuşma): Celal Bayar Üniversitesi
Mezuniyet Sonrası Eğitim Toplantısı, Manisa, 30 Nisan 2003.
K3. İnal M.M., “Gebelik Önleyici Yöntemler ve Yenilikler” (Konuşma): 2. Ulusal
Hemşirelik Kongresi, İzmir, 15 Mayıs 2003.
K4. İnal M.M., “Sağlık Bakanlığı İmplant Kontrasepsiyon Türkiye Pilot Uygulamasının 1
Yıllık Sonuçları Paneli” (Panelist): 4. Ulusal Jinekoloji ve Obstetrik Kongresi, Antalya, 2025 Nisan 2004.
17
K5. İnal M.M., 5. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi (Davetli
Konuşmacı), 19-22 Nisan 2007.
K6. İnal M.M., 5. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi (Danışma
Kurulu Üyeliği), 19-22 Nisan 2007.
K7. İnal M.M., 2. Güncel Üreme Endokrinolojisi, YÜT Kongresi ve 1. Üreme Tıbbı Derneği
Kongresi (Ulusal Bilimsel Kurul Üyeliği), 17-20 Nisan 2008.
L. Atıflar:
L1. (A2). Taskin, O., Onoglu, A., M. Inal, Turan, E., Sadik, S., Vardar, E., Postaci, H.,
Wheeler J.M., “Long-term Histopathologic and Morphologic Changes after Thermal
Endometrial Ablation. J Am Assoc Gynecol Laparosc, 9 (2): 186-190, (2002).
L1.1. Dan Y., Yat-May W., Ying C., Enlan X., Tin-Chiu L., “Asherman syndrome—
one century later”, Fertility and Sterility, 89 (4): 759–779 (2008).
L1.2. Nappi, C., Di Spiezio, A., Greco, E., Guida, M., Bettocchi, S., Bifulco, G.,
“Prevention of adhesions in gynaecological endoscopy”, Human Reproduction
Update, 13 (4): 379–394 (2007).
L1.3.
McCausland,
AM.,
McCausland,
VM.,
“Long-term
complications
of
endometrial ablation: Cause, diagnosis, treatment, and prevention”, Journal of
Minimally Invasive Gynecology, 14 (4): 399–406 (2007).
L1.4. Mukul, LV., Linn, JG., “Pregnancy complicated by uterine synechiae after
endometrial ablation”, Obstet Gynecol, 105 (5 Pt 2): 1179-82 (2005).
L1.5. Shaamash, AH., Sayed, EH., “Prediction of successful
menorrhagia
treatment after thermal balloon endometrial ablation”, Journal of Obstetrics and
Gynaecology Research, 30 (3): 210–216 (2004).
L1.6. Liha, L., Huiyi H., Jiali, K., Linghong, D., “Thermal Balloon Endometrial
Clinical Study of Therapy for the Treatment of Menorrhagia”, China Practical
Gynaecology and Obstetrics, (2003).
L1.7. Onoglu, A., Taskin, O., Inal, M., Sadik, S., Simsek, M., Akar, M., Kursun, S.,
Ispahi, C., “Comparison of the Long-term Histopathologic and Morphologic
18
Changes after Endometrial Rollerball Ablation and Resection: A Prospective
Randomized Trial”, The J Min Inv Gyn, 14 (1): 39-42, (2007).
L1.8. Wyss, P., Caduff, R., Tadir, Y., Degen, A., Wagnières, G., Schwarz, V.,
Haller, U., Fehr, M., “Photodynamic Endometrial Ablation: Morphological Study”,
Lasers in Surgery and Medicine, 32 (4): 305–309 (2003).
L1.9. Hua, D., Yanjie, L., Lng, L., Yi, Y., Enlan, X., “Research on repairing
patterns and factors causing subsequent surgery after trancervical resection of
endometrium”, Chinese Journal of Obstetrics and Gynaecology, 38 (12): (2003).
L1.10. Laberge, PY., “Serious and deadly complications from pregnancy after
endometrial ablation: Two case reports and review of the literatüre”, Journal de
Gynécologie Obstétrique et Biologie de la Reproduction, 37 (6): 609–613, (2008).
L1.11. Enlan, X., “Removal of Second Generation of Endometrium”, Chinese
Journal of Obstetrics and Gynaecology, 39 (12): (2004).
L1.12. Geping, Y., Tong-Yu, Z., Ming, C., Shujun, Y., “Long-term Effect on
Radiofrequency Heat-Coagulation Endometrial Ablation in the Treatment of
Anovulatory Dysfunctional Uterine Bleeding”, Chinese Journal of Obstetrics and
Gynaecology, 9 (3): 73-75 (2011).
L1.13. Feng, L., Gao, W., Yang, B., Wang, W., Zhao, W., Wei, L., “Clinical
Analysis of Abnormal Uterine Bleeding Treatment with Thermablate EAS”, Journal
of Peking University (Health Sciences), 38 (4): 432-435 (2006).
L1.14.
McCausland,
AM.,
McCausland,
VM.,
“Long-Term
Complications
of
Minimally Invasive Endometrial Ablation Devices”, Journal of Gynecologic Surgery,
26 (2): 133-149 (2010).
L1.15.
Ahonkallioa,
SJ.,
Liakkab,
AK.,
Martikainena,
HK.,
Santalaa,
MJ.,
“Feasibility of endometrial assessment after thermal ablation”, European Journal
of Obstetrics & Gynecology and Reproductive Biology, 147 (1): 69-71 (2009).
L1.16. Brun, JL., Galant, C., Delvaux, D., Lemoine, P., Henriet, P., Courtoy, PJ.,
Marbaix, E., “Menstrual activity of matrix metalloproteinases is decreased in
endometrium regenerating after thermal ablation”, Hum. Reprod, 24 (2): 333340 (2009).
L1.17. Geping, Y., Ming, C., Tong Yu, Z., Xiaoli, Z., “The mechanism of two newly
developed
endometrial
ablation
procedures
using
radiofrequency
19
thermocoagulation for the treatment of dysfunctional uterine bleeding”, Chinese
Journal of Obstetrics and Gynaecology, 12 (6): (2011).
L1.18. Yujie, L., Sufang, S., Yanmin, W., “Influence of Progesterone On
Expression of EGFR、VEGF and KDF after Endometrectomy”, Applied Journal of
General Practice, 3 (1): (2008).
L1.19. Jialing, T., Suhua, X., Ye, M., Xiuxing, Z., “The clinical analysis of thermal
balloon endometrial ablation on 30 cases with menorrhagia”, Guangzhou Medical
Journal, 37 (6): (2006).
L1.20. Gepin, Y., Zu, LJ., Yu T., Ming, C., “Estrogen receptor and progesterone
receptor expression and mechanism of endometrium of anovulatory dysfunctional
uterine bleeding treated with Radiofrequency heat-coagulation”, Chinese Journal
of Clinical Medicine for Women and Children, 12 (1): 175-181 (2010).
L1.21. Qin, T., Volt, LX., “Thermal Balloon Method Combined with Drug
Treatment of Menorrhagia”, Journal of Shanxi Medical University, 37 (5): 544-545
(2006).
L1.22. Hui, X., “Non-Hysteroscopic Endometrial Surgery”, Foreign Medical
Sciences (Obstet-Gynecol Fascicle), 29 (4): (2002).
L1.23. Dan, Z., Yandang, L., Yan, M., Lin, Z., “Ultrasonographic evaluation of
uterine hemodynamics following transcervical resection of endometrium”, Chinese
Journal of Medical Ultrasonography, 2 (1): (2005).
L1.24. Mishra, K., Manucha, V., Sengupta, R., Singh, K., Aggarwal, N.,
“Cytomorphology and Histomorphology After Thermal Endometrial Ablation”, Acta
Cytologica 47 (6): 1001-1007 (2003).
L1.25. Yujie, L., Sufang, S., “Endometrial resection assisted with clinical
observation of methyl-hydroxyprogesterone”, Shandong Medical Journal, 12 (3):
(2006).
L1.26. Lei, Z., Yan, D., Ma, J., Wang, F., Buaijiaer, J., “Resection of endometrium
for endometrial atypical hyperplasia clinical observation of 28 cases”, Journal of
Xinjiang Medical University, p. 1384-1386 (2011).
L1.27. Avci, ME., Sadik S., Uçar MG., “A Prospective Study of Rollerball
Endometrial Ablation in the Management of Refractory Recurrent Symptomatic
20
Endometrial Hyperplasia without Atypia”, Gynecol Obstet Invest, 74 (4): 282–287
(2012).
L1.28. Izue, C., “Clinical study on treatment of dysfunctional uterine bleeding
with Thermal balloon endometrial removal”, Chinese Journal of Rural Medicine and
Pharmacy, 8 (3): (2005).
L1.29. Geping, Y,, Tongyu, Z., Juan, L., Ming, C., Shujun, Y., Xiaoli, Z.,
“Decreased expression of survivin, estrogen and progesterone receptors in
endometrial tissues after radiofrequency treatment of dysfunctional uterine
bleeding”, World Journal of Surgical Oncology, 10 (1): 100 (2012).
L1.30. Alhilli, MM.,
Wall, DJ.,
Brown, DL.,
Weaver, AL.,
Hopkins, MR.,
Famuyide, AO., “Uterine ultrasound findings after radiofrequency endometrial
ablation: correlation with symptoms”, Ultrasound Quarterly, 28 (4): 261-268
(2012).
L1.31. Hongxiu, L., Qingling, Y., “Vacuum thermal balloon treatment for
menopausal transitional dysfunctional uterine bleeding”, Chinese Community of
Physicians, 9 (12): (2010).
L1.32. Yan, D., “The guiding significance of Caspase-3 in patients with
hydatidiform mole before they reproduce”, Journal of Xinjiang Medical University,
p. 1387-1389 (2011).
L1.33. Gimpelson, RJ., Bieber, EJ., Loffer, FD., "The role of repeat procedures and
second-look
hysteroscopes
in
endometrial
ablation/resection",
Gynecologic
Hysteroscopy, Resectoscopy and Endometrial Ablation p.201 (2003).
L1.34. Chunfang, L., “Peri-menopausal dysfunctional uterine bleeding treatment”,
Chinese Medicine of Factory and Mine, 19 (2): (2006).
L1.35. Park, H., Seong, SJ., Yoon, BS., “The effect of operative hysteroscopy
conducted before progestin treatment in early stage endometrial cancer from the
view of fertility”, Gynecol Oncol, 123 (2): 427-8 (2011).
L1.36.
Ahonkallio,
S.,
“Endometrial
Thermal
Ablation”,
Acta
Universitatis
Ouluensis D Medica, 1205, (2013).
L1.37. Xiaolin, LV., “TB-endometrium study and clinical application of therapy for
the treatment of dysfunctional uterine bleeding”, Journal of Maternal and Child
Healthcare of China, 2 (1): (2011).
21
L1.38. Qingfen, Y., Aiqin, Y., Shehong, H., “Hysteroscope in treating submucosal
myoma of uterus, uterine SEPTA and clinical analysis of intrauterine foreign body”,
Chinese Journal of Traditional Chinese and Western Medicine, 11 (5): (2004).
L1.39. Yujie, L., Sufang, S., “Effect of progesterone on endometrial EGFR, KDR
and VEGF expression after TRCE”, Shandong Medical Journal, 15 (4): (2008).
L1.40. Simionescu, C., Margaritescu, CL., Stepan, A., Ciurea, R., Cernea, N.,
“Uterine pseudotumors”, Rom J Morphol Embryol, 52 (3): 743–758 (2011).
L1.41. Clark, JT., Dupuch, L., Balchin, I., Byrne, DL., Frappell, JM., “Variable
pressure cornual resection. Does radical hysteroscopic surgery give better
results?”, Gynecological Surgery, 3 (3): 180-185 (2006).
L1.42.
Chunxia,
D.,
Guang,
S.,
Liya,
G.,
“Clinical
study
on
climacteric
dysfunctional uterine bleeding treated with thermal balloon endometrial ablation
and hysteroscopic endometrial electroresection”, Journal of Maternal and Child
Healthcare of China, 26 (36): (2011).
L1.43. Qin, Y., “Care for Metropathia Hemorrhagica Patients Receiving Thermal
Endometrial Ablation: A report of 51 cases”, Chinese Journal of General Practice,
12 (17): (2009).
L1.44. Qiumeini, L., Tang, Q., “Perimenopausal endometrial disease combined
with TCRE-hydroxyprogesterone treatment
efficacy”, China
Foreign
Medical
Treatment, 31 (11): (2012).
L1.45. Duleba, AJ., "Pediatrics Ob/GYN Family Practice Business of Healthcare"
(2004).
L1.46. Bruno, R., and D. E. Townsend. "Hysteroscopic Evaluation Following
Endometrial Ablation", (2004).
L1.47. Duleba, A.J., “What do Endometrial Cryoablation and Cryomyolysis have to
Offer?”, Contemporary Ob/Gyn, 50 (3): 56-65 (2005).
L1.48. El-Saman, A., Mohammad, HSE., Zakhera, MS., Zahran, KM., Ahmad, EM.,
Salem, AO., “Tactile Electrosurgical Ablation: A New Technique for Endometrial
Ablation-A Preliminary Study”, Med. J. Cairo Univ, 78 (1): 241-246 (2010).
22
L2. (A24). M.M. Inal, Kose, S., Yildirim, Y., Ozdemir, Y., Toz, E., Ertopcu, K., Ozelmas,
I., Tinar, S., “The Relationship Between HPV Infection and Cervical Intraepithelial
Neoplasia (CIN) in Turkish Women”, Int J Gynecol Cancer, 17 (6): 1266–1270 (2007).
L2.1. Dursun, P., Altuntaş, B., Kuşçu, E., Ayhan, A., “Women's knowledge about
human papillomavirus and their acceptance of HPV vaccine”, Australian and New
Zealand Journal of Obstetrics and Gynaecology, 49 (2): 202–206 (2009).
L2.2. Dursun, P., Senger, SS., Arslan, H., Kuşçu, E., Ayhan, A., “Human
papillomavirus (HPV) prevalence and types among Turkish women at a gynecology
outpatient unit”, BMC Infectious Diseases, 9: 191 (2009).
L2.3. Usubütün, A., Alemany, L., Küçükali, T., Ayhan, A., Yüce, K., de Sanjosé,
S., Font, R., Lloveras, B., Klaustermeier, J., Quint, W., Muñoz, N., Bosch, FX.,
“Human papillomavirus types in invasive cervical cancer specimens from Turkey”,
Int J Gynecol Pathol, 28 (6): 541-8 (2009).
L2.4. Yılmaz, HH., Yazıhan, N., Tunca, D., Sevinç, A., Olcayto, EO., Özgül, N.,
Tuncer, M., “Cancer Trends and Incidence and Mortality Patterns in Turkey”, Jpn.
J. Clin. Oncol, 41 (1): 10-16 (2011).
L2.5. Darnel, AD., Wang, D., Ghabreau, L., Yasmeen, A., Sami, S., Akil, N., Al
Moustafa,
AE.,
“Correlation
between
the
presence
of
high-risk
human
papillomaviruses and Id gene expression in Syrian women with cervical cancer”,
Clinical Microbiology and Infection, 16 (3): 262–266 (2010).
L2.6. Yavuzer, D., Karadayi, N., Salepci, T., Baloglu, H., Dabak, R., Bayramicli,
OU., “Investigation of human papillomavirus DNA in colorectal carcinomas and
adenomas”, Medical Oncology, 28 (1): 127-132 (2011).
L2.7. Eren, F., Erenus, M., Bas, E., Ahiskali, R., Yoldemir, T., “Prevalence of HPV
infection by cytologic diagnosis and HPV DNA extraction and prevalence of the
HPV genotypes detected in urban Turkish women”, International Journal of
Gynecology & Obstetrics, 109 (3): 235–238 (2010).
L2.8. Durusoy, R., Yamazhan, M., Taşbakan, MI., Ergin, I., Aysin, M., Pullukçu,
H., Yamazhan, T., “HPV Vaccine Awareness and Willingness of First-Year Students
Entering University in Western Turkey”, Asian Pacific J Cancer Prev, 11: 1-6
(2010).
23
L2.9. Mehmetoglu, HC., Sadikoglu, G., Ozcakir, A., Bilgel, N., “Pap smear
screening in the primary health care setting: A study from Turkey”, N Am J Med
Sci, 2 (10): 467–472 (2010).
L2.10. Bayram, A., Erkılıç, S., Balat, Ö., Ekşi, F., Gürol, M., Öztürk, E., Kaya, G.,
“Prevalence and genotype distribution of human papillomavirus in non-neoplastic
cervical tissue lesion: Cervical erosion”, Journal of Medical Virology, 83 (11):
1997–2003 (2011).
L2.11. Atilgan, R., Celik, A., Boztosun, A., Ilter, E., Yalta, T., Ozercan, R.,
“Evaluation of cervical cytological abnormalities in Turkish population”, Indian J
Pathol Microbiol, 55 (1): 2-5 (2012).
L2.12. Seoud, M., “Burden of human papillomavirus-related cervical disease in
the extended middle East and north Africa-a comprehensive literature review”, J
Low Genit Tract Dis, 16 (2): 106-20 (2012).
L2.13. Yavuzer, D., Salepci, T., Karadayi, N., Baloglu, H., Kucukodaci, Z, “Human
papillomavirus is not associated with breast carcinoma”, Breast Cancer Research
and Treatment, 122 (3): 899-900 (2010).
L2.14. Yuce, K., Pinar, A., Salman, MC., Alp, A., Sayal, B., Dogan, S., Hascelik,
G., “Detection and genotyping of cervical HPV with simultaneous cervical cytology
in Turkish women: a hospital-based study”, Archives of Gynecology and
Obstetrics, 286 (1): 203-208 (2012).
L2.15. Vaccarella, S., Bruni, L., Seoud, M., “Burden of Human Papillomavirus
Infections and Related Diseases in the Extended Middle East and North Africa
Region”, Vaccine, 31 (6): 32–44 (2013).
L2.16. Karadayi, N., Gecer, M., Kayahan, S., Yamuc, E., Onak, NK., Korkmaz, T.,
Yavuzer, D.,
“Association
between
human
papillomavirus and
endometrial
adenocarcinoma”, Medical Oncology, 30: 597 (2013).
L2.17. Demir, ET., Ceyhan, M., Simsek, M., Gunduz, T., Arlier, S., Aytac, R.,
Aycan, AE., Gurbuz, V., “The prevalence of different HPV types in Turkish women
with a normal Pap smear”, Journal of Medical Virology, 84 (8): 1242–1247
(2012).
24
L2.18. Dursun, P., et al. “HPV Types in Turkey: Multicenter Hospital Based
Evaluation of 6388 Patients in Turkish Gynecologic Oncology Group Centers”,
Turkish Journal of Pathology, 29 (3): 210–216 (2013).
L2.19. Ozdaş, S., Bozdayı, G., Demirağ, A., Onan, A., Taşkıran, C., Ilhan, MN.,
“Diagnosing Human Papillomavirus and Human Papillomavirus Type 16 by
Realtime PCR in Patient Undergone to Colposcopy and Significance of the
Diagnosis”, J Turk Soc Obstet Gynecol, 10: 79-89 (2013).
L2.20. Tuncer, M., ed. “Türkiye'de Kanser Harcamaları ve Maliyet Etkinlik
Çalışmaları”, TC Sağlık Bakanlığı, (2009).
L2.21. Ozyer, S., Uzunlar, O., Ozler, S., Kaymak, O., Baser, E., Gungor, T.,
Mollamahmutoglu, L., “Awareness of Turkish Female Adolescents and Young
Women about HPV and their Attitudes Towards HPV Vaccination”, Asian Pac J
Cancer Prev, 14 (8): 4877-4881 (2013).
L2.22. Mehmetoğlu, HC., et al. "Screening for Cervical Cancer with Pattern of Pap
Smear. A Study among Married Women Attended to a Primary Health Care Unit in
Turkey." N Am J Med Sci, 2 (10): 467-72 (2010).
L2.23. Altun, Z., Yarkın, F., Vardar, MA., Uğuz, AH., “The Prevalence of Human
Papilloma Virus Infection Among Women who Admitted to Çukurova University
Faculty of Medicine Hospital”, Turkiye Klinikleri J Med Sci, 31 (2): 307-14 (2011).
L2.24. Tonguc, E., Gungor, T., Var, T., Kavak, E., Yucel, M., Uzunlar, O.,
“Knowledge about HPV, relation between HPV and cervix cancer and acceptance of
HPV vaccine in women in eastern region of Turkey”, J Gynecol Oncol, 24 (1): 713 (2013).
L2.25. Ersan, G., Kose, S., Senger, SS., Gunes, H., Sehirali, S., Gurbuz, I., “The
Prevalence and Risk Factors of Human Papillomavirus in Female Sex Workers”,
Eurasian Journal of Medicine, 45: 16-20 (2013).
L2.26. Yavuzer, D., Karadayı, N., Erdağlı, A., Salepçi, T., Baloğlu, H., Dabak, R.,
“Serviks Kanseri ve Prekanseröz Lezyonlarında PCR ile HPV Tiplemesi”, Kartal
Eğitim ve Araştırma Hastanesi Tıp Dergisi, XX (1): 1-6 (2009).
L2.27. Özalp, SS., Us, T., Arslan, E., Öge, T., Kaşifoğlu, N., “HPV DNA and Pap
smear test results in cases with and without cervical pathology”, J TurkishGerman Gynecol Assoc, 13: 8-14 (2012).
25
L2.28. Akyar, I., Aydın, Ö., Yakıcıer, M., Tanıl, Z., “Human Papillomavirus
prevalence and type in liquid-based cervical samples from Turkish women in a
selected risk group”, Turkish Journal of Medical Sciences, 43 (6): 963-970
(2013).
L2.29. Özcan, ES., Taşkin, S., “High-risk human papilloma virus prevalence and
its relation with abnormal cervical cytology among Turkish women”, Journal of
Obstetrics and Gynaecology, 31 (7): 656-658 (2011).
L2.30. Ardıç, N., Ozturk, O., Ergünay, K., Sezer, O., “Servikal Sürüntü
Örneklerinde Yüksek Riskli İnsan Papilloma Virus Tiplerine Ait E6/E7 mRNA’larının
Ticari Otomatize Bir NASBA Sistemiyle Araştırılması”, Mikrobiyol Bul, 43: 463-469
(2009).
L2.31. Özgün, G., Aydoğdu, G., “Distribution of Uterin Cervical Lesions and
Relation Between Age and Parity Rates in the Mardin Province”, Turkish Journal of
Pathology, 29 (1): 46–50 (2013).
L2.32. Eren, H., Özgüneş, N., Bayram, Y., Güzin, K., Parlak, M., “Serviksin
Prekanseröz Lezyonlarında Human Papilloma Virus (HPV) Tiplerinin Belirlenmesi”,
Van Tıp Dergisi, 20 (2): 70-75 (2013).
L2.33. Cilli, M., Methiyev, S., Şimşek, A., Kadıoğlu, A., “Cinsel yol ile bulaşan
hastalıklar”, Androloji Bülteni, 42 (3): 167-174 (2010).
L2.34. Güdücü, N., Gönenç, G., İşçi, H., Yiğiter, AB., Dünder, İ., “Awareness of
human papilloma virus, cervical cancer and HPV vaccine in healthcare workers and
students of medical and nursing schools”, J Clin Exp Invest, 3 (3): 318-325
(2012).
L2.35.
Altun,
Z.,
“Çukurova
Bölgesindeki
Kadınlarda
Genital
Human
Papillomavirus İnfeksiyon Prevalansı”, Çukurova Üniversitesi Mikrobiyoloji Bilim
Dalı, Doktora Tezi (2009).
L2.36. Karabulut, Y., Dölek, Y., Kurşun, N., "Documentation of cervical cytological
findings in Çankırı population." Cumhuriyet Medical Journal (CMJ), 34 (4): 441446 (2012).
26
L3 (A13). Yildirim, Y., M.M. Inal, Tinar, S., “Reproductive and Obstetric Characteristics
of Adolescent Pregnancies in Turkish Women”, J Pediatr Adolesc Gynecol, 18 (4): 249253 (2005).
L3.1. Usta, IM., Zoorob, D., Abu-Musa, A., Naassan, G., Nassar, AH., “Obstetric
outcome of teenage pregnancies compared with adult
pregnancies”, Acta
Obstetricia et Gynecologica Scandinavica, 87 (2): 178-183 (2008).
L3.2. Magalhães, MLC., Furtado, FM., Nogueira, MB., “Precocious and late
pregnancy in adolescents – is there a difference comparing the obstetric risks?”,
Rev Bras Ginecol Obstet, 28 (8): 443-446 (2006).
L3.3. Rocha, RCL., Souza, E., Guazzelli, CAF., Filho, AC., Soares, EP., Nogueira,
ES., “Prematurity and low weight of newborns from primiparous adolescents
according to age groups”, Rev Bras Ginecol Obstet, 28 (9): 530-5 (2006).
L3.4. Briggs, MM., Hopman, WM., Jamieson, MA., “Comparing pregnancy in
adolescents and adults: obstetric outcomes and prevalence of anemia”, J Obstet
Gynaecol Can, 29 (7): 546-55 (2007).
L3.5. Kuo, CP., Lee, SH., Wu, WY., Liao, WC., Lin, SJ., Lee, MC., “Birth outcomes
and risk factors in adolescent pregnancies: Results of a Taiwanese national
survey”, Pediatrics International, 52 (3): 447–452 (2010).
L3.6. Rocha, RCL., Souza, E., Soares, EP., Nogueira, ES., Filho, AC., Guazzelli,
CAF., “Prematurity and Low Birth Weight among Brazilian Adolescents and Young
Adults”, Journal of Pediatric and Adolescent Gynecology, 23 (3): 142–145 (2010).
L3.7. Duvan, CI., Turhan, NÖ., Onaran, Y., Gümüş, II., Yuvacı, H., Gözdemir, E.,
“Adolescent Pregnancies: Maternal and Fetal Outcomes”, The New Journal of
Medicine, 27: 113-116 (2010).
L3.8. Arkan DC., Kaplanoğlu, M., Kran, H., Ozer, A., Coskun, A., Turgut, E.,
“Adolescent pregnancies and obstetric outcomes in Southeast Turkey: data from
two regional centers”, Clinical and experimental obstetrico & gynecology, 37 (2):
144-147 (2010).
L3.9. Ünalan, PC., Kaya, ÇA., Akgün, T., Yıkılkan, H., Isgör, A., “Birinci
Basamakta Ergen Sağlığına Yaklaşım”, Turkiye Klinikleri J Med Sci, 27: 567-576
(2007).
27
L3.10. Atchara, C., Hornboonherm, P., "Comparative Study in Perception of
Unwanted Pregnancy between Secondary School and Undergraduate Students."
International Conference, Faculty of Nursing. Mahasarakham University, Thailand
(2010).
L3.11. Uzun, AK., Orhon, FS., Baskan, S., Ulukol, B., “A comparison between
adolescent mothers and adult mothers in terms of maternal and infant outcomes
at follow-ups”, Journal of Maternal-Fetal and Neonatal Medicine, 26 (5): 454-458
(2013).
L3.12. Karabulut, A., Ozkan, S., Bozkurt, AI., Karahan, T., Kayan, S., “Perinatal
outcomes and risk factors in adolescent and advanced age pregnancies:
Comparison with normal reproductive age women”, Journal of Obstetrics &
Gynaecology, 33 (4): 346-350 (2013).
L3.13. Demirgöz, M., Canbulat, N., “Adölesan Gebelik”, Turkiye Klinikleri J Med
Sci, 28 (6): 947-52 (2008).
L3.14. Mitin, MY., “Prevalence and incidence of gynaecological structure in
adolescence”, Russian State Medical University, Graduate Thesis (2005).
L3.15. Suwannobol, N., Chobkhayan, S., “Outcomes of Teenage Mothers at
Dankhunthot
Hospital,
Nakhon
Ratchasima”,
World
Academy
of
Science,
Engineering and Technology, 71: 409-411 (2012).
L3.16. Taminato, M., Saconato, H., Fram, DS., Dulce, AB., “Screening strategies
for GBS during prenatal care for the prevention of early-onset infection:
systematic review and meta-analysis”, 12th International Nursing Research
Conference, Evidence based practice, session 19, Spain, 2008.
L3.17. Col-Araz, N., “Evaluation of factors affecting birth weight and preterm
birth in southern Turkey”, JPMA, 63 (4): 459-462 (2013).
L3.18. Yıldızhan, R., Kolusarı, A., Edirne, T., Adalı, E., Erol, Ş., Kurdoğlu, M.,
Kurdoğlu, Z., “Van Yöresinde Adolesan Gebeliklerin Analizi”, Van Tıp Dergisi, 16
(4): 124-127 (2009).
L3.19. Rezavand, N., Zangane, M., Khosravi, M., Rezaee, M., “A comparative
study of pregnancy results in adolescents and young mothers referred to the
Motazedi hospital in Kermanshah”, Journal of Urmia Nursing and Midwifery
Faculty, 7 (3): 191-192 (2009).
28
L3.20. Lezcano, SAS., Arce, MSV., Sodero, H., “Comparative study of low-birth
weight, 1st minute to depression and termination cesarean between adolescent
motherrs and general population”, Revista de Posgrado de la VIa Cátedra de
Medicina, 150: 1-3 (2005).
L4. (A23). Onoglu, AS., Taskın, O., M. Inal, Sadik S., “Comparison of the Long Term
Histopathologic and Morphologic Changes after Endometrial Roller-ball Ablation and
Resection: A Prospective Randomized Trial”, The J Min Inv Gyn, 14 (1): 39-42 (2007).
L4.1. Ahonkallio, SJ., Liakka, AK., Martikainen, HK., Santala, MJ., “Feasibility of
endometrial assessment after thermal ablation”, European Journal of Obstetrics &
Gynecology and Reproductive Biology, 147 (1): 69-71 (2009).
L4.2. Sharp, HT., “Endometrial ablation: postoperative complications”, American
Journal of Obstetrics & Gynecology, 207 (4): 242-247 (2012).
L4.3. Stetkiewicz, T., Stachowiak, G., Surkont, G., et al. “Hysteroscopy use in
modern diagnostics and therapy”, Przegląd Menopauzalny, 3: 173–176 (2007).
L4.4. Yanna, L., Zhang, T., Tao, L., “Long-Term Efficacy and Safety of Thermal
Balloon Endometrial Ablation for Patients with Menorrhagia”, Chinese Journal of
Minimally Invasive Surgery, 9: (2009).
L4.5. Xiao, L., Yan, L., Zhijun, J., Lamei, H., Jing, C., “Radiofrequency induced
thermal endometrial ablation in treatment of menorrhagia: a 2 years follow-up”,
Shanghai Medical Journal, 31 (5): 320 (2008).
L4.6. Maia, HJ., Haddad, C., Casoy, J., Maia, R., Pinheiro, N., Coutinho, EM.,
“Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and
Cox-2 expression in patients with adenomyosis submitted or not, to endometrial
resection”, Int J Womens Health, 4: 175–183 (2012).
L4.7. Guizhi, L., Bin, L., Jinghua, S., “Clinical study on dysfunctional uterine
bleeding treated with uterine thermal balloon”, Maternal and child health care of
China, 34: (2010).
29
L4.8. Avci, ME., Sadik, S., Uçar, MG., “A Prospective Study of Rollerball
Endometrial Ablation in the Management of Refractory Recurrent Symptomatic
Endometrial Hyperplasia without Atypia”, Gynecol Obstet Invest, 74 (4): 282–287
(2012).
L4.9. Ming, W., “The History, Situation and Future of Hysteroscopic Endometrial
Ablation”, Journal Of International Obstetrics And Gynecology, 39 (5): (2012).
L4.10. Alhilli, MM.,
Wall, DJ.,
Brown, DL.,
Weaver, AL.,
Hopkins, MR.,
Famuyide, AO., “Uterine ultrasound findings after radiofrequency endometrial
ablation: correlation with symptoms”, Ultrasound Quarterly, 28 (4): 261-268
(2012).
L4.11. Dan, H., Ming-guo, T., Yi, Q., Dong-liang, Y., Wei-bing, S., “Elimination of
high-risk elderly patients with acute cholecystitis under the fistula endoscopy via
gallbladder mucosa”, Chinese Journal of Endoscopy, 18 (1): (2012).
L4.12. Wei-lan, X., Guang-liang, Z., Xiao-li, Z., Li-ping, H., Jing-yu, HE., Shi-jiao,
C., ” Retrospective analyse of climacteric dysfunctional uterine bleeding treated
with TCRE and TBEA”, The Journal of Practical Medicine, 28 (21): (2012).
L4.13. Pérez-López, R., Simoncini, T., Tremollieres, F., Rees, M., Ulrich, LG.,
“EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal
women”, Maturitas, 75 (2): 181-190 (2013).
L4.14. Liping, H., Fengbin, J., Ling, Z., “Third generation thermal balloon
endometrial therapy for the treatment of dysfunctional uterine bleeding: analysis
of 51 cases”, Chinese Journal of Misdiagnostics,
12 (5): (2012).
L4.15. Bin, L., Jinghua, S., Mei, W., Hua, L., “Comparative study on Nuoshu
(NovaSure) with thermal balloon for the treatment of abnormal uterine bleeding”,
Chinese Journal of Obstetrics and Gynecology, 47 (3): (2012).
L4.16. Ahonkallio, S., “Endometrial
thermal
ablation”,
ACTA, Universitatis
Ouluensis, D 1205, Oulu (2013).
L4.17. Xiaoqin, X., Haiyan, S., Hongmei, Z., Guorong, X., “Resection of
endometrium in treatment of abnormal uterine bleeding: analysis of 38 cases”,
Clinical Medicine of China, 29: (2013).
30
L4.18. Holt, R., Santiago-Muñoz, P., Nelson, DB., Twickler, D., “Sonographic
findings in two cases of complicated pregnancy in women previously treated with
endometrial ablation”, J. Clin. Ultrasound, 41 (9): 566–569 (2013).
L4.19. Zeng-zhen, L., Ju-jie, D., “Radiofrequency ablation in treatment of
abnormal uterine bleeding in 82 Cases”, Practical Journal of Clinical Medicine, 10
(5): (2013).
L4.20. Chun-Xia, D., Guang, S., Li-Ya, G., “Clinical study on climacteric
dysfunctional uterine bleeding treated with thermal balloon endometrial ablation
and hysteroscopic endometrial electroresection”, Maternal and Child Health Care
of China, 26 (36): (2012).
L4.21. Mingguo, T., Yunjuan, Q., Dan, H., Xinyuan, W., “Gallbladder Mucosal
Ablation by Hysteroscopic Rollerball Electrocoagulation after Cholecystostomy”,
Chinese Journal of minimally invasive surgery, 8 (12): (2008).
L4.22. Dreisler, E., Poulsen, L.G., Antonsen, S.L., et al, “EMAS clinical guide:
assessment of the endometrium in peri and postmenopausal women”, Maturitas,
75 (2): 181–190, (2013).
L5. (A19). M.M. Inal, Yildirim, Y., Taner, CE., “Comparison of the Clinical Efficacy of
Flutamide and Spironolactone plus Diane 35 in the Treatment of Idiopathic Hirsutism: A
Randomized Controlled Study”, Fertil Steril, 84 (6): 1693-1697 (2005).
L5.1. Martin, KA., Chang, RJ., Ehrmann, DA., Ibanez, L., et al. “Evaluation and
Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical
Practice Guideline”, The Journal of Clinical Endocrinology & Metabolism, 93 (4):
1105-1120 (2008).
L5.2. Blume-Peytavi, U., Hahn, S., “Medical treatment of hirsutism”, Dermatologic
Therapy, 21 (5): 329–339 (2008).
L5.3. Radosh, L., “Drug Treatments for Polycystic Ovary Syndrome”, American
Family Physician, 79 (8): (2009).
L5.4. Karakurt, F., Sahin, I., Güler, S., Demirbas, B., Culha, C., Serter, R., Aral,
Y., Bavbek, N., “Comparison of the clinical efficacy of flutamide and spironolactone
plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A
randomised controlled study”, Advances in Therapy, 25 (4): 321-328 (2008).
31
L5.5. Al Robaee, A., Al-Zolibani, A., Al-Shobaili, HA., Aslam, M., “Update on
hirsutism”, Acta Dermatoven APA, 17 (3): 103-119 (2008).
L5.6. Branco, CC., Cancelo, MJ., “Comprehensive clinical management of
hirsutism”, Gynecological Endocrinology, 26 (7): 484-493 (2010).
L5.7.
Maharaj,
S.,
Amod,
A.,
“Polycystic
ovary
syndrome”,
Journal
of
Endocrinology, Metabolism and Diabetes of South Africa, 14 (2): 86-95 (2009).
L5.8. Pizzo, A., Borrielli, I., Raffone, E., Vaiarelli, A., Stella, NC., “The interference
of the flutamide on the sexual differentiation of a male fetüs. A case report”,
Giornale italiano di ostetricia e ginecologia, 31 (8/9): 363-365 (2009).
L5.9.
Kriplani,
A.,
Thulkar,
J.,
Agrawal,
N.,
Kulshrestha,
V.,
et
al,
“A Comparative Study of Diane‐35 plus spironolactone and Diane ‐35 Plus Finasteri
de in Cases of Hirsutism and Acne”, Int J Endocrinol Metab, 7 (4): 235-241
(2009).
L5.10. Lakshmi, C., “Hormone therapy in acne”, Indian J Dermatol Venereol
Leprol, 79 (3): 322-37 (2013).
L5.11. Jiang-yuan, L., “Idiopathic hirsutism and its diagnosis and treatment”,
Chinese Journal of practical internal medicine, 27 (23): (2007).
L5.12. Palacios, A., “Advances in the diagnosis and treatment of hirsutism in
adolescent
and
young
adult”,
Revista
Venezolana
de
Endocrinología
y
Metabolismo, 6 (1): 35-38 (2009).
L5.13. Blume-Peytavi, U., “How to diagnose and treat medically women with
excessive hair”, Dermatologic Clinics, 31 (1): 57-65 (2013).
L5.14. Caswell, AH., “Evolutionary Basis of Homosexuality – a Hypothesis of
Socio-sexual Interaction”, (2011).
L5.15. Czernichow, PRP., “GH treatment of non growth hormone deficient short
stature”, Rev. Venez. Endocrinol. Metab, 6 (1): 27-29 (2008).
L5.16. Pugeat, M., Kaddar, N., Raverot, V., “Recommended Treatment Modalities
for Hyperandrogenism”, Polycystic Ovary Syndrome: Contemporary Endocrinology
pp 295-306 (2008).
32
L5.17. Metwally, M., “Hirsutism”, Obstetrics, Gynaecology & Reproductive
Medicine, 22 (8): 211–214 (2012).
L5.18. Hernandez-Escareno, A., "Comparing The Hormone, Metabolic, And Lipid
Profiles
Of
Reproductive
Age
Women
And
The
Effects
Of
Dried
Apple
Supplementation And Resistance Exercise In Women With Polycystic Ovary
Syndrome",
Florida
State
University,
Electronic
Theses,
Treatises
and
Dissertations. Paper 4086 (2009).
L5.19. Lumachi, F., Zulian, E., Scaroni, C., “Cost-effective Therapy in Patients
with Idiopathic Hirsutism”, Expert Review of Pharmacoeconomics and Outcomes
Research, 4 (3): 297-306 (2004).
L5.20. Sahin, Y., Kelestimur, F., “Medical Treatment Regimens of Hirsutism”,
Reproductive BioMedicine Online, 8 (5): 538-546 (2004).
L5.21. Reismann, P., Liko, I., Patocs, A., “Pharmacological options for treatment
of hyperandrogenic disorders”, Mini Reviews in Medicinal Chemistry, 9: (9): 11131126 (2009).
L5.22.
2013
Treatment
Compendium
of
of Clinical
Hirsutism
in
Practice Guidelines;
Premenopausal
http://dx.doi.org/10.1210/CCPG.9781936704668.ch20;
Evaluation
Women,
Published
and
DOI:
Online:
November 20, 2013.
33
L6 (A16). Yildirim, Y., M.M. Inal, Sanci, M., Yildirim, YK., Mit, T., Polat, M., Tinar, S.,
“Development of Uterine Sarcoma after Tamoxifen Treatment for Breast Cancer: Report
of Four Cases”, Int J Gynecol Cancer, 15 (6): 1239-1242 (2005).
L6.1. Moinfar, F., Azodi, M., Tavassoli, FA., “Uterine sarcomas”, Pathology, 39
(1): 55-71 (2007).
L6.2. Huang, GS., Gunter, MJ., Arend, RC., Li, M., Arias-Pulido, H., Prossnitz, ER.,
Goldberg, GL., Smith, HO., “Co-expression of GPR30 and ERβ and their
association with disease progression in uterine carcinosarcoma”, American Journal
of Obstetrics & Gynecology, 203 (3): 242.e1 -242.e5 (2010).
L6.3. Lavie, O., Barnett-Griness, O., Narod, SA., Rennert, G., “The risk of
developing
uterine sarcoma
after
tamoxifen
use.
International
Journal
of
Gynecological Cancer, 18 (2): 352–356 (2008).
L6.4. Teo, SY., Babagbemi, KT., Peters, HE., Mortele, KJ., “Primary Malignant
Mixed Müllerian Tumor of the Uterus: Findings on Sonography, CT, and
Gadolinium-Enhanced MRI”, American Journal of Roentgenology, 191 (1): 278283 (2008).
L6.5. Harry, VN., Narayansingh, GV., Parkin, DE., “Uterine leiomyosarcomas: a
review
of
the
diagnostic
and
therapeutic
pitfalls”,
The
Obstetrician
&
Gynaecologist, 9 (2): 88–94 (2007).
L6.6. Gottwald, L., Gora, E., Korczynski, J., Piekarski, JH., Morawiec, Z., JesionekKupnicka, D., Sowa, P., Cialkowska-Rysz, A., Bienkiewicz, A., “Primary uterine
rhabdomyosarcoma
in
a
patient
with
a
history
of
breast
cancer
and
gastrointestinal stromal tumor”, Journal of Obstetrics and Gynaecology Research,
34 (4): 721–725 (2008).
L6.7. Suprasert, P., Khunamornpong, S., “Carcinosarcoma arising in uterine
didelphys after tamoxifen therapy for breast cancer: a case report”, J Med Assoc
Thai, 93 (5): 608-12 (2010).
L6.8. Buccoliero, AM., Fambrini, M., Gheri, CF., Castiglione, F., Garbini, F.,
Barbetti, A., et al. “Surveillance for Endometrial Cancer in Women on Tamoxifen:
The Role of Liquid-Based Endometrial Cytology – Cytohistological Correlation in a
Population of 168 Women”, Gynecol Obstet Invest, 65 (4): 240–246 (2008).
34
L6.9. Saim, M., Cote, JF., Morel, O., Malartic, C., Akerman, G., Gray, F.,
Barranger, E., “Malignant mixed müllerian tumor of the uterus following tamoxifen
for breast cancer: Case report”, Gynécologie Obstétrique & Fertilité, 36 (2): 166–
168 (2008).
L6.10. Homer, L., Muller, M., Dupre, PF., Lucas, B., Pradier, O., “Uterine sarcoma
associated with tamoxifen use after breast cancer: Review of the pathogenesis”,
Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 38 (8): 629–
633 (2009).
L6.11. Brennan, MF., Antonescu, CR., Maki, RG., “Leiomyosarcoma”, Management
of Soft Tissue Sarcoma, p.113-127 (2013).
L6.12. Yıldırım, Y., Toz, E., “The Effect of Long-Term Tamoxifen Usage on the
Lower Part of Female Genital Tract in Breast Cancer Survivors: A Review”,
Marmara Medical Journal, 20 (3): 196-201 (2007).
L6.13. Xiaonan, Z., Jingliang, C., Feifei, W., Mengtian YS., “One case: malignant
mixed Mullerian tumor of the uterus”, Practical Journal of Radiology, 29 (8):
(2013).
L6.14. van Meurs, HS., Dieles, JJ., Stel, HV., “A uterine leiomyoma in which a
leiomyosarcoma with osteoclast-like giant cells and a metastasis of a ductal breast
carcinoma are present”, Annals of Diagnostic Pathology, 16 (1): 67–70 (2012).
L6.15. Vasconcelos, ALC., Nunes, B., Duarte, C., Mendonca, V., Ribeiro, J., Jorge,
M., Grillo, IM., “Tamoxifen in breast cancer ipse dixit in uterine malignant mixed
Müllerian tumor and sarcoma—A report of 8 cases and review of the literature”,
Reports of Practical Oncology & Radiotherapy, 18 (5): 251–260 (2013).
L6.16. Caramelo, O., Marinho, C., Rebelo, T., et al., “A Case of Endometrial
Stromal Sarcoma with Synchronous Bilateral Adenocarcinoma of Ovary,” Case
Reports in Obstetrics and Gynecology, 2012: 1-5 (2012).
L6.17. Koukouliata, A., “Malignant mixed mullerian tumor in two patients
receiving tamoxifen therapy”, Prog Health Sci, 1 (1): 167-170 (2011).
L6.18. Barry, L., Baxter, G., Pitchamuthu, H., Crooks, JE., Rajan, P., Ahmad, I.,
“Aggressive bladder leiomyosarcoma in a patient receiving tamoxifen therapy”,
Journal of Clinical Urology, 6: 327-329 (2013).
35
L6.19. Shor, AC., "Src kinase inhibitors for the treatment of sarcomas: Cellular
and molecular mechanisms of action", Graduate School Theses and Dissertations,
University of South Florida (2007).
L7 (A27). Onay H., Ugurlu T., Aykut A., Pehlivan S., M. Inal, Tinar S., Ozkinay C.,
Ozkinay F., “Rapid prenatal diagnosis of common aneuploidies in amniotic fluid using
quantitative fluorescent polymerase chain reaction”, Gynecol Obstet Invest, 66 (2): 10410 (2008).
L7.1. Cirigliano, V., Voglino, G., Ordoñez, E., Marongiu, A., Paz Cañadas, M.,
Ejarque, M., Rueda, L., Lloveras, E., Fuster, C., Adinolfi, M., “Rapid prenatal
diagnosis of common chromosome aneuploidies by QF-PCR, results of 9 years of
clinical experience, Prenat. Diagn, 29 (1): 40–49 (2009).
L7.2. Faas, BHW., Cirigliano, V., Bui, TH., “Rapid methods for targeted prenatal
diagnosis of common chromosome aneuploidies”, Seminars in Fetal & Neonatal
Medicine, 16 (2): 81-87 (2011).
L7.3. Yan，C., Yu-ning，Z.,
Shi-ming，L.,
Jian-fei，Y., Yu, M., “Establishment
and Application of 18-STR Database in Han Population from Zhejiang Province”, J
SUN Yat-sen Univ (Med Sci)，31 (1)：122-128 (2010).
L7.4. Langlois, S., Duncan, A., “Use of a DNA method, QF-PCR, in the prenatal
diagnosis of fetal aneuploidies”, J Obstet Gynaecol Can, 33 (9): 955-60 (2011).
L7.5. Rivkees, SA., Hager, K., Hosono, S., Wise, A., Li, P., Rinder, HM., Gruen,
JR., “A Highly Sensitive, High-Throughput Assay for the Detection of Turner
Syndrome”, The Journal of Clinical Endocrinology & Metabolism, 96 (3): (2011).
L7.6. Yan-Ping, L., Jing C., Shu-Fang, J., Zhang, L., Zhi-Ying, G., et al.
“Development of Multiple Quantitative Fluorescent PCR for Rapid Diagnosis of
Common Aneuploidy and It's Clinical Application”, Heredity, 11 (32): 1141-1146
(2010).
L7.7. Xiangyu, Z., Yali, H., “Advances in diagnosis of fetal chromosomal
abnormalities methods”, Chinese Journal of perinatal medicine, 12 (2): (2009).
36
L7.8.
Allingham-Hawkins,
DJ.,
Tokunaga, J., Winsor, E.,
fluorescent
polymerase
Chitayat,
D.,
Cirigliano,
V.,
Summers,
A.,
Chun, K., “Prospective validation of quantitative
chain
reaction
for
rapid
detection
of
common
aneuploidies”, Genetics in Medicine, 13 (2): 140–147 (2011).
L7.9. Ai-qun, X., Xu-ming, B., Jun-tao, L., Feng-xia, Y., Wei-min, Z., Na, H., Jing,
Z., “Establishment of multiple quantitative fluorescent polymerase chain reaction
assay and its application in rapid prenatal diagnosis of common chromosome
aneuploidies”, Chinese Journal of obstetrics and Gynecology, 45 (7): (2010).
L7.10. Atef, SH., Hafez, SS., Mahmoud, NH., Helmy, SM., “Prenatal diagnosis of
fetal aneuploidies using QF-PCR: the egyptian study”, J Prenat Med, 5 (4): 83–89
(2011).
L7.11. Manlong, Q., Yuanyuan, Z., Harpole, LX., Zhao, Y., “QF-PCR in the
diagnosis of chromosomal abnormality in male infertility”, Genetic, 8: (2011).
L7.12. Scott, P., Podemski, L., Wyatt, KB., Walker, C., et al. “Toward Optimal
Detection of the Common Prenatal Aneuploidies by Quantitative Fluorescent–
Polymerase Chain Reaction: Comparison of Two Commercial Assays”, Genetic
Testing and Molecular Biomarkers, 16 (8): 943-947 (2012).
L7.13. Ozturk, E., Ugur, MG., Cebesoy, FB., Aydın, A., Sever, T., Balat, O., “Good
prognosis for primary ovarian pure nongestational choriocarcinoma using the
EMA/CO regime”, Eur. J. Gynaec. Oncol, 31 (1): 123-125 (2010).
L7.14. Wei, J., Lei, F., “Human short tandem repeat sequence correlation
technique and its application in forensic science progress”, Chinese Journal of New
Clinical Medicine, 11: (2011).
L7.15. Dikensoy, E., Balat, O., Pehlivan, S., Cebesoy, FB, Kutlar, AI., Sever, T.,
Baltacı, V., “A false negative QF-PCR and Trisomy 18-Trisomy 9 mosaicism”, J
Turk Soc Obstet Gynecol, 8 (1): 67- 70 (2011).
L7.16. Helmy, SMH., Essawi, M., Bassiouni, R., Gaber, KR., “Rapid PNCD for
Common Aneuploidies Uusing QF-PCR in Egyptian Women”, Research Journal of
Medicine and Medical Sciences, 4 (2): 446-451 (2009).
37
L7.17. Furtado, LV., Jama, MA, Paxton, CN., Wilson, AA., Gardiner, AE., Lyon, E.,
Geiersbach, KB., “Aneuploidy Detection in Paraffin Embedded Tissue from
Products of Conception by Mini-STR Genotyping”, Fetal & Pediatric Pathology, 32
(2): 133-150 (2013).
L7.18. Güngör, ANÇ., Hacıvelioğlu, S., Uludağ, A., Gencer, M., et al “Fetal
Anöploidi Açısından Yüksek Riskli Gebeliklerin QF-PCR İle Analizi”, International
Journal of Clinical Research, 1 (1): 17-21 (2013).
L8 (A8). M.M. Inal, Hanhan, M., Pilanci, B., Tinar, S., “Fallopian Tube Malignancies:
Experience of Social Security Agency Aegean Maternity Hospital”, Int J Gynecol Cancer,
14 (4): 595-599, (2004).
L8.1.
Pectasides,
D.,
Pectasides,
E.,
Economopoulos,
T.,
“Fallopian
Tube
Carcinoma: A Review”, The Oncologist, 11 (8): 902-912 (2006).
L8.2. Goodman, MT., Shvetsov, YB., “Incidence of Ovarian, Peritoneal, and
Fallopian Tube Carcinomas in the United States, 1995-2004”, Cancer Epidemiol
Biomarkers Prev, 18 (1): 132-139 (2009).
L8.3. Bendavid, C., Pasquier, L., Watrin, T., Morcel, K., Lucas, J., et al.
“Phenotypic variability of a 4q34 → qter inherited deletion: MRKH syndrome in the
daughter, cardiac defect and Fallopian tube cancer in the mother”, European
Journal of Medical Genetics, 50 (1): 66–72 (2007).
L8.4. Kietpeerakool, C., Suprasert, P., Srisomboon, J., Pantusart, A., “Primary
Carcinoma of the Fallopian Tube: A Clinicopathologic Analysis of 27 Patients”, J
Med Assoc Thai, 88 (10): 1338-43 (2005).
L8.5. Lin, CX., Shanling, WL., Xiao, X., Xuemei, Z., “Primary Fallopian Tube
Carcinoma: A Clinical Analysis of 25 Patients”, Practical Journal of Obstetrics and
Gynecology, 24 (5): (2008).
L8.6. Goswami, PK., Kerr-Wilson, R., McCarthy, K., “Cancer of the fallopian tube”,
The Obstetrician & Gynaecologist, 8 (3): 147–152 (2006).
L8.7. Yane, Z., Bright, L., River, D., “One Case:Bilateral Calcific Carcinoma of
Fallopian Tube”, Practical Journal of Radiology, 24 (8): (2008).
38
L8.8. Stein, RG., Diessner, J., Hönig, A., Wischhusen, J., Dietl, J., “Fallopian tube
tumors: an overview”, Atlas of Genetics and Cytogenetics in Oncology and
Haematology, 17 (11): 773-787 (2013).
L8.9. Ştefănescu, BI., Muscă, S., Ştefănescu, RM., Pricop, M., şi Farmacie, FD. M.,
“Primitive Fallopian Tube Carcinoma – About 3 Cases. Clinical Study”, ObstetricăGinecologie II, 10 (1): 140-145 (2011).
L8.10. Giri, SK., Nayak, B., “Malignancy and Fallopian Tubes: An In-depth Study”,
in The Fallopian Tubes, ed., Tripathy, SN., 17: 149-154 (2013).
L8.11. Kalampokas, E., Kalampokas, T., Tourountous, I., “Primary fallopian tube
carcinoma”, European Journal of Obstetrics & Gynecology and Reproductive
Biology, 169 (2): 155–161 (2013).
L8.12. Shuzhi, D., Bin, S., “The original tubal adenocarcinoma metastatic
carcinomas to spleen: 1 case report and literature review”, Journal of Hebei
Medical University, 31 (2): (2010).
L8.13. Yuanjing, H., Fengxia, X., “Retroperitoneal lymphadenectomy influence on
survival prognosis of primary Carcinoma of fallopian tube”, The Chinese Journal of
practical Gynecology and obstetrics, 2010: 443-445 (2010).
L8.14. Jianqin, H., Li, W., Zhiling, Z., “Analysis of 22 cases with primary fallopian
tube carcinoma diagnosis”, Chinese Journal of Cancer, 21 (8): (2011).
L8.15. Aiqin, R., Yu, L., “Fallopian tube carcinoma misdiagnosed as Carcinoma of
the vagina: analysis of 1 cases”, Chinese Journal of Misdiagnosis, 24: (2011).
L8.16.
Yue, L., Chun, H., Liping, Y., Jingjing, L., “Double uterus with
endometrium and fallopian tubes of double tumor of 1 cases”, The journal of
practical obstetrics and Gynecology, 25 (3): (2009).
L8.17. Bharti, MK., Chauhan, A., Sabharwal, R., “Primary Fallopian Tube
Adenocarcinoma: A Case Report”, IJPSR, 2 (11): 3002-3005 (2011).
39
L9 (A25). M.M. Inal, Yildirim Y., Ertopcu K., Avci ME., Ozelmas I., Tinar S., “Effect of
the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and
hormonal parameters (three years follow-up)”, Eur J Contracept Reprod Health Care, 13
(3): 238-42 (2008).
L9.1. Brito, MB., Ferriani, RA., Quintana, SM., Yazlle, MEHD., de Sá, MFS., Vieira,
CS.,
“Safety
of
the
etonogestrel-releasing
implant
during
the
immediate
postpartum period: a pilot study”, Contraception, 80 (6): 519–526 (2009).
L9.2. Li, HWR., Wong, CYG., Yeung, WSB., Ho, PC., Ng, EHY., “Serum antimüllerian hormone level is not altered in women using hormonal contraceptives”,
Contraception, 83 (6): 582–585 (2011).
L9.3. Dilbaz, B., Ozdegirmenci, O., Caliskan, E., Dilbaz, S., Haberal, A., “Effect of
etonogestrel implant on serum lipids, liver function tests and hemoglobin levels”,
Contraception, 81 (6): 510–514 (2010).
L9.4. Arribas-Mir, L., Rueda-Lozano, D., Agrela-Cardona, M., Cedeño-Benavides,
T., Olvera-Porcel, C., Bueno-Cavanillas, A., “Insertion and 3-year follow-up
experience of 372 etonogestrel subdermal contraceptive implants by family
physicians in Granada, Spain”, Contraception, 80 (5): 457–462 (2009).
L9.5.
Brito,
MB.,
Nobre,
F.,
Vieira,
CS.,
“Hormonal
Contraception
and
Cardiovascular System”, Arq. Bras. Cardiol, 96 (4): 81-89 (2011).
L9.6. Oderich, CL., Wender, MCO., Lubianca, JN., Santos, LM., de Mello, GC.,
“Impact of etonogestrel-releasing implant and copper intrauterine device on
carbohydrate metabolism: a comparative study”, Contraception, 85 (2): 173–176
(2012).
L9.7. Hohmann, H., “Examining the efficacy, safety, and patient acceptability of
the etonogestrel implantable contraceptive”, Patient Prefer Adherence, 3: 205–
211 (2009).
L9.8. Guazzelli, CAF., de Queiroz, FT., Barbieri, M., Barreiros, FA., Torloni, MR.,
Araujo,
FF.,
“Metabolic
effects
of
contraceptive
implants
in
adolescents”,
Contraception, 84 (4): 409–412 (2011).
40
L9.9. Zal, F., Mostafavi-Pour, Z., Amini, F., Heidari, A., “Effect of vitamin E and C
supplements on lipid peroxidation and GSH-dependent antioxidant enzyme status
in the blood of women consuming oral contraceptives”, Contraception, 86 (1):
62–66 (2012).
L9.10.
Oderich,
CL.,
“Estudo
comparativo
do
Implante
Subdérmico
de
Etonogestrel e do DIU de Cobre no Metabolismo dos Carboidratos”, PhD Thesis,
Universidade Federal do Rio Grande do Sul, (2010).
L9.11.
Jin-jin, L., Xin-yan, L., “The Clinical
Etonogestrel
Implant”,
International
journal
Performance of
of
reproductive
Single Rod
health/family
planning, 4: (2013).
L9.12. Bruni, V., Seravalli, V., Scarselli, G., “Contraccezione ormonale e rischio
cardiovascolare”, SIC Donna news, 5 (2): 4-30 (2012).
L9.13. Brito, MB., Ferriani, RA., Quintana, SM., de sá, MFS., Vieira, CS., “Absence
of adverse hepatic or renal effects with the etonogestrel-releasing contraceptive
implant inserted immediately postpartum”, Open Access Journal of Contraception,
1: 127–133 (2010).
L9.14. Milica, B., Milica, M., “Hormonska kontracepcija - prednosti i zablude”,
Medicinski Podmladak, 60 (1-2): 133-138 (2009).
L9.15. Hedderson, M., “Contraception Before and After GDM”, Gestational
Diabetes During and After Pregnancy, 21: 317-329 (2010).
L10 (A26). Yildirim Y., Gultekin E., Avci ME., M.M. Inal, Yunus S., Tinar S., “Cardiac
safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime
cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal
cancer”, Int J Gynecol Cancer, 18 (2): 223-7 (2008).
L10.1. Zhang, Y., Shi, J., Li, Y., Wei, L., “Cardiomyocyte death in doxorubicininduced cardiotoxicity”, Archivum Immunologiae et Therapiae Experimentalis, 57
(6): 435-445 (2009).
L10.2. Fjällskog, MLH., Janson, ET., Falkmer, UG., Vatn, MH., Öberg, KE.,
Eriksson,
BK.,
“Treatment
with
Combined
Streptozotocin
and
Liposomal
Doxorubicin in Metastatic Endocrine Pancreatic Tumors”, Neuroendocrinology, 88:
53–58 (2008).
41
L10.3. Paoli, EE., Kruse, DE., Seo, JW., Zhang, H., Kheirolomoom, A., et al. “An
optical and microPET assessment of thermally-sensitive liposome biodistribution in
the Met-1 tumor model: Importance of formulation”, Journal of Controlled
Release, 143 (1): 13–22 (2010).
L10.4. Duggan, ST., Keating, GM., “Pegylated Liposomal Doxorubicin”, Drugs, 71
(18): 2531-2558 (2011).
L10.5. Strother, R., Matei, D., “Pegylated liposomal doxorubicin in ovarian
cancer”, Ther Clin Risk Manag, 5: 639–650 (2009).
L10.6. Steer, CB., “Chemotherapy for Ovarian Cancer in the Older Adult”, Current
Treatment Options in Oncology, 10 (3-4): 159-170 (2009).
L10.7. Maradia, K., Guglin, M., “Pharmacologic prevention of anthracyclineinduced cardiomyopathy”, Cardiol Rev, 17 (5): 243-52 (2009).
L10.8.
Yiwei,
Z.,
Yuanjian,
L.,
“Recent
insights
into
doxorubicin-induced
cardiomyocyte death”, International Journal of Clinical and Pathological Science,
2: (2011).
L10.9. Henderson, IC., “Development of PEGylated Liposomes, in Drug Delivery in
Oncology: From Basic Research to Cancer Therapy (eds F. Kratz, P. Senter and H.
Steinhagen)”, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2011).
L10.10. Ceyhan, C., Turgut, H., "Acute Transient Diastolic Dysfunction Induced
By 5-Fluorouracil Treatment: A Case Report”, Journal of Cardiac Research TM, 32:
(2005).
L10.11.
Lyseng-Williamson,
KA.,
Duggan,
ST.,
Keating,
GM.,
“Pegylated
Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies”, BioDrugs, 27
(5): 533-540 (2013).
L10.12. Hartung, GA., Mansoori, GA., “In vivo General Trends, Filtration and
Toxicity of Nanoparticles”, Journal of Nanomaterials & Molecular Nanotechnology,
2 (3): 1-21 (2013).
L10.13. Zhenhua, Z., Jingbo, W., “Cytotoxicity Effect of Thermo-chemotherpy
with Pegylated Liposomal Doxorubicin on Human Esophageal Carcinoma in vitro”,
Cancer Research on Prevention and Treatment, 38 (7): (2011).
42
L10.14. Zhang, Y., Zhang, Q., Zeng, SX., Hao, Q., Lu, H., “Inauhzin Sensitizes
p53-Dependent
Cytotoxicity
and
Tumor
Suppression
of
Chemotherapeutic
Agents”, Neoplasia, 15 (5): 523–534 (2013).
L10.15. Mansoori, G.A., “In vivo General Trends, Filtration and Toxicity of
Nanoparticles”, Journal of Nanomaterials & Molecular, 2013
L11 (A18). M.M. Inal, Incebiyik, A., Sanci, M., Yildirim, Y., Polat, M., Pilanci, B., Nayki,
C., Camuzcuoglu, H., “Ovarian Cysts in Tamoxifen-Treated Women with Breast Cancer”,
Eur J Obstet Gynecol Reprod Biol, 120 (1): 104-106 (2005).
L11.1. Fleming, JS., Beaugié, CR., Haviv, I., Chenevix-Trench, G., Tan, OL.,
“Incessant
ovulation,
inflammation
and
epithelial
ovarian
carcinogenesis:
Revisiting old hypotheses”, Molecular and Cellular Endocrinology, 247 (1–2): 4–
21 (2006).
L11.2. Peano, BJ., Crabtree, JS., Komm, BS., Winneker, RC., Harris, HA., “Effects
of Various Selective Estrogen Receptor Modulators with or without Conjugated
Estrogens on Mouse Mammary Gland”, Endocrinology, 150 (4): 1897-1903
(2009).
L11.3. Harris, HA., Chennathukuzhi, VM., Zhang, X., Mekonnen, B., et al.
”Development of an early biomarker for the ovarian liability of selective estrogen
receptor modulators in rats”, The Journal of Steroid Biochemistry and Molecular
Biology, 112 (1-3): 40–46 (2008).
L11.4. Lin, L., Shu-zhen, W., Zhen-yu, Z., Yan, Z., Hong-chuan, J., Jie, L.,
“Follow-up of benign gynecologic diseases in patients treated with tamoxifen for
breast cancer”, National Medical Journal of China, 25: (2010).
L11.5. Baigent, A., Lashen, H., “Ovarian hyperstimulation syndrome in a patient
treated with tamoxifen for breast cancer”, Fertility and Sterility, 95 (7): 2429.e5–
2429.e7 (2011).
L11.6. Mofrad, MH., Shandiz, FH., Roodsare, FV., Toktam Moghima, T.,
“Evaluation of Ovarian Cysts in Breast Cancer Cases on Tamoxifen”, Asian Pacific J
Cancer Prev, 11: 161-164 (2010).
43
L11.7. Qin Wu, Q., Xiaozhong, C., Yiyong, W., “Effects of Tamoxifen on uterus
and ovary in patients with breast cancer”, Chongqing Medicine Journal, 36 (16):
(2007).
L11.8. Oliva, P., Roncoroni, C., Radaelli, E., Brunialti, E., Rizzi, N., De Maglie, M.,
Scanziani, E., et al. “Global Profiling of TSEC Proliferative Potential by the Use of a
Reporter Mouse for Proliferation”, Reproductive Sciences, 20 (2): 119-128
(2013).
L11.9. Yıldırım, Y., Toz, E., “The Effect of Long-term Tamoxifen Usage on the
Lower PArt of Female Genital Tract in Breast Cancer Survivors: A Review”,
Marmara Medical Journal, 20 (3): 196-201 (2007).
L11.10. Guastalla, J.P., Tredan, O., Ray-Coquard, I., Labidi, I., Bonnin, N.,
Bachelot, T. L “Hormonothérapie adjuvante (produits, durée) doit-elle être
modulée par le profil biologique de la tumeur (niveau d’hormonosensibilité, statut
d’HER2 et prolifération)”, Cancer, 2006,
pp 385-399 (2006).
L11.11. Hsiao, W., Weimin, K., Xiunan, L., Yi, D., “Endocrine therapy for breast
cancer and its impact on female genital mutilation”, The Chinese Journal of
practical Gynecology and Obstetrics, 1 (3): 817-819 (2008).
L11.12. Zhonglin, F., Haiping, L., Cuizhi, G., Yun-Tao, L., “Changes of serum
estradiol and follicular stimulating hormone after tamoxifen treatment in breast
cancer cases”, Chinese Journal of Clinical Physicians, 1: (2012).
L11.13. Matiluko, AF., Crystal, AM., “Adnexal torsion in a postmenopausal woman
on tamoxifen”, Trends Urology, Gynecol. Sexual Health, 14 (5): 30–32 (2009).
L12 (A17). M.M. Inal, Ertopcu, K., Ozelmas, I., “The Evaluation of 318 Intrauterine
Pregnancy Cases with An Intrauterine Device”, Eur J Contracept Reprod Health Care, 10
(4): 266-271 (2005).
L12.1. Van Oppenraaij, RHF., Jauniaux, E., “Predicting adverse obstetric outcome
after early pregnancy events and complications: a review”, Hum. Reprod. Update,
15 (4): 409-421 (2009).
44
L12.2. Merki-Feld, GS., Schwarz, D., Imthurn, B., Keller, PJ., “Partial and
complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing IUD
after correct insertion”, European Journal of Obstetrics & Gynecology and
Reproductive Biology, 137 (1): 92–96 (2008).
L12.3. Ganer, H., Levy, A., Ohel, I., Sheiner, E., “Pregnancy outcome in women
with an intrauterine contraceptive device”, American Journal of Obstetrics and
Gynecology, 201 (4): 381.e1–381.e5 (2009).
L12.4. Yu, J., Li, J., Li, H., Li, J., Xie, C., Zhu, C., “Comparative study on
contraceptive
efficacy
and
clinical
performance
of
the
copper/low-density
polyethylene nanocomposite IUD and the copper T220C IUD”, Contraception, 78
(4): 319–323 (2008).
L12.5. Snell, BJ., “Assessment and Management of Bleeding in the First Trimester
of Pregnancy”, Journal of Midwifery & Women’s Health, 54 (6): 483–491 (2009).
L12.6. Brahmi, D., Steenland, MW., Renner, RM, Gaffield, ME., Curtis, KM.,
“Pregnancy outcomes with an IUD in situ: a systematic review”, Contraception, 85
(2): 131–139 (2012).
L12.7. Moschos, E., Twickler, DM, ”Intrauterine devices in early pregnancy:
findings on ultrasound and clinical outcomes”, American Journal of Obstetrics and
Gynecology, 204 (5): 427.e1–427.e6 (2011).
L12.8. Gyang, A., Mirando, S., “Gräfenberg ring retained for 15 years: A case
report”, The European Journal of Contraception and Reproductive Health Care, 11
(4): 319-321 (2006).
L12.9. Owen, C., Sober, S., Schreiber, CA., “Controversies in family planning:
desired pregnancy, IUD in situ and no strings visible”, Contraception, 88 (3):
330-3 (2013).
L12.10. Mirena IUD Lawsuit Moves, Mirena IUD Helpline Watches. "The Mirena
IUD is Manufactured by Bayer..." (2013).
L12.11. Veloso, MD., Lobos, AG., Aliste, SN., Rojas, GC., García, MP., Matzler,
PP., “Post-insertion ultrasonographic control of intrauterine device”, Rev Chil
Obstet Ginecol, 76 (1): 15 – 20 (2011).
45
L12.12. Rowen, T., Creinin, MD., “Highlights (and lowlights) from the past year in
contraception: the US unintended pregnancy rate and controversies in providing
contraception”, Update: Contraception, 24 (8): 29-35 (2012).
L12.13. Dean, G., Goldberg, AB., Zieman, M., Barss, VA., “Overview Of Mirena
IUD Complications, Medical Perspective”, Mirena IUD Lawsuit News, (2013).
L13. (A3). Taner, C., M. Inal, Basogul, O., Onoglu, A., Karanfil, C., Tinar, S., Ispahi, C.,
“Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus an
Oral Contraceptive in the Treatment of Hirsutism”, Gynecol Obstet Invest, 54 (2): 105108 (2002).
L13.1. Koulouri, O., Conway, GS., “A systematic review of commonly used
medical treatments for hirsutism in women”, Clinical Endocrinology, 68 (5): 800–
805 (2008).
L13.2.
Escobar-Morreale,
HF.,
Carmina,
E.,
Dewailly,
D.,
Gambineri,
A.,
Kelestimur, F., Moghetti, P., et al. “Epidemiology, diagnosis and management of
hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary
Syndrome Society”, Hum. Reprod. Update, 18 (2): 146-170 (2012).
L13.3. Castelo-Branco, C., Moyano, D., Gómez, O., Balasch, J., “Long-term safety
and tolerability of flutamide for the treatment of hirsutism”, Fertility and Sterility,
91 (4): 1183–1188 (2009).
L13.4. Sahin, Y., Kelestimur, F., “Medical treatment regimens of hirsutism”,
Reproductive BioMedicine Online, 8 (5): 538–546 (2004).
L13.5. Al-Robaee, A., Al-Zolibani, A., Al-Shobaili, HA., Aslam, M., “Update on
hirsutism”, Acta Dermatoven APA, 17 (3): 103-119 (2008).
L13.6. Paradisi, R., Venturoli, S., “Retrospective observational study on the
effects and tolerability of flutamide in a large population of patients with various
kinds of hirsutism over a 15-year period”, Eur J Endocrinol, 163 (1): 139-147
(2010).
L13.7. Castelo-Branco, C., Cancelo, MJ., “Comprehensive clinical management of
hirsutism”, Gynecological Endocrinology, 26 (7): 484-493 (2010).
46
L13.8. Lis-huang, M., Mei-yu, Y., Xiao-ke, W., “Treatment of adolescent polycystic
ovary syndrome”, Foreign medical sciences (maternal and child health division),
16 (3): (2005).
L13.9. Lumachi, F., Zulian, E., Scaroni, C., “Cost-effective therapy in patients
with idiopathic hirsutism”, Expert Review of Pharmacoeconomics & Outcomes
Research, 4 (3): 297-306 (2004).
L13.10. Hartmann, KE., Jerome, RN., Lindegren, ML., et al. “Primary Care
Management
of
Abnormal
Uterine
Bleeding”,
Rockville
(MD):
Agency
for
Healthcare Research and Quality (US); Comparative Effectiveness Reviews, No. 96
(2013).
L13.11. Manieri,
DC., Di Bisceglie,
C., Brocato, L., “Terapia farmacologica di
irsutismo e androgenizzazione”, L’Endocrinologo, 4 (3): 118-130 (2003).
L14. (A4). Vardar, E., Maral, I., M. Inal, Ozguder, O., Tasli, F., Postaci, H.,
“Comparison of Gram Stain and Pap Smear Procedures in the Diagnosis of Bacterial
Vaginosis”, Infect Dis Obstet Gynecol, 10 (4): 203-207 (2002).
L14.1. Fitzhugh, VA., Heller, DS., “Significance of a diagnosis of microorganisms
on pap smear”, J Low Genit Tract Dis, 12 (1): 40-51 (2008).
L14.2. Eriksson, K., Forsum, U., Bjornerem, A., Platz-Christensen, JJ., Larsson,
PG., ”Validation of the use of Pap-stained vaginal smears for diagnosis of bacterial
vaginosis”, APMIS, 115 (7): 809–813 (2007).
L14.3. Niño, LR., Manzanero, RZ., Urdaneta, JC., Martínez, VG., Maribel, N.,
“Bacterial vaginosis: evaluation of diagnostic methods”, Kasmera, 32 (1): 43-51,
(2004).
L14.4. Eriksson, K., Adolfsson, A., Forsum, U., Larsson, PG., “The prevalence of
BV in the population on the Åland Islands during a 15-year period”, APMIS, 118
(11): 903–908 (2010).
L14.5. Ngaojaruwong, N., Vuthiwong, C., et al. “Prevalence of Abnormal
Papanicolaou Smear in Pregnant Women at Phramongkutklao Hospital”, Thai
Journal of Obstetrics and Gynaecology, 16 (3): 179-185 (2008).
47
L14.6. Alves, VAF., Filho, AC., Namiyama, G.,
Filho, AL., et al. “Liquid-based
cytology by DNA-Cytologic system (DCS) – efficacy in identification of vaginal
microflora”, DST – J bras Doenças Sex Transm, 16 (4): 27-31 (2004).
L14.7. Eriksson, K., “Bacterial Vaginosis: Diagnosis, Prevalence, and Treatment”,
Linköping University Electronic Press, Linköping, (2011).
L14.8. Karasahin, E., Gungor, S., Ceyhan, ST., Keskin, U., Baser, I., “The
association of contraceptive usage with the frequency of the most common
etiological agents of vaginal infection”, Balkan Military Medical Review, 11 (1):
34-39 (2008).
L15. (A15). Sehirali, S., M.M. Inal, Yildirim, Y., Balim, Z., Kosova, B., Karamizrak, T.,
Sanci, M., Topcuoglu, N., Tinar,
S., “Prothrombin G20210A Mutation in Cases with
Recurrent Miscarriage: A Study of the Mediterranean Population”, Arch Gynecol Obstet,
273 (3): 170-173 (2005).
L15.1. Toth, B., Vocke, F., Rogenhofer, N., Friese, K., Thaler, CJ., Lohse, P.,
“Paternal Thrombophilic Gene Mutations Are Not Associated with Recurrent
Miscarriage”, American Journal of Reproductive Immunology, 60 (4): 325–332
(2008).
L15.2. Zoossmann-Diskin, A., Gazit, E., Peleg, L., Shohat, M., Turner, D.,
“Thrombophilic polymorphisms in Israel”, Blood Cells, Molecules, and Diseases, 41
(2): 230–233 (2008).
L15.3. Glueck, CJ., Pranikoff, J., Khan, N., Riaz, K., et al. “High factor XI,
recurrent pregnancy loss, enoxaparin”, Fertility and Sterility, 94 (7): 2828–2831
(2010).
L15.4. Zoossmann-Diskin, A., “The origin of Eastern European Jews revealed by
autosomal, sex chromosomal and mtDNA polymorphisms”, Biology Direct, 5 (1):
57-75 (2010).
L15.5. Zonouzi, AP., Chaparzadeh, N., Ghorbian, S., Sadaghiani, MM., et al. “The
association between thrombophilic gene mutations and recurrent pregnancy loss”,
Journal of Assisted Reproduction and Genetics, 30 (10): 1353-1359 (2013).
48
L15.6. Gawish, GEH., Al-Khamees, O., “Molecular Characterization of Factor V
Leiden G1691A and Prothrombin G20210A Mutations in Saudi Females with
Recurrent Pregnancy Loss”, J Blood Disorders Transf, 4 (6): 1-7 (2013).
L16. (A12). Yildirim, Y., Tinar, S., Yildirim, YK., M.M. Inal, “Comparison of PituitaryOvarian Function in Patients Who Have Undergone Successful Renal Transplantation and
Healthy Women”, Fertil Steril, 83 (5): 1553-1556 (2005).
L16.1. Douglas, NC., Shah, M., Sauer, MV., “Fertility and Reproductive Disorders
in Female Solid Organ Transplant Recipients”, Seminars in Perinatology, 31 (6):
332-338 (2007).
L16.2. Abe, T., Ichimaru, N., Okumi, M., Imamura, R., Isaka, Y., Takahara, S.,
Kokado, Y. Okuyama, A., “Pregnancy after renal transplantation: A single-center
experience”, International Journal of Urology, 15 (7): 587–592 (2008).
L16.3. Richman, K., Gohh, R., “Pregnancy after renal transplantation: a review of
registry and single-center practices and outcomes”, Nephrol. Dial. Transplant, 27
(9): 3428-3434 (2012).
L16.4. Gassen, DT., Herter, LD., Garcia, C., Marroni, R., Maiga Milagre, M.,
Barros, V., “Hormonal aspects of gynecological patients with transplanted kidney
and Nefropathies”, Revista HCPA, 29 (3): (2009).
L16.5. Yıldırım, Y., Sönmez, S., Toz, E., İnal, M., Aykas, A., Uslu, A., “Solid organ
(kidney, liver, pancreas-kidney, heart, lung and heart-lung) transplantations and
pregnancy”, Marmara Medical Journal, 21 (1): 79-88 (2008).
L16.6. Kim, JM., Song, RK., Kim, MJ., Lee, DY., Jang, HR., Kwon, CHD., et al.
“Hormonal Differences Between Female Kidney Transplant Recipients and Healthy
Women With the Same Gynecologic Conditions”, Transplantation Proceedings, 44
(3): 740-743 (2012).
L16.7. Pietrzak, B., Wielgos, M., Kaminski, P., Jabiry-Zieniewicz, Z., Bobrowska,
K.,
“Menstrual
Cycle
and
Sex
Hormone
Profile
in
Kidney-Transplanted
Women”, Neuroendocrinology Letters, 27 (1-2): 198-202 (2006).
49
L17. (A22). M.M. Inal, Yildirim, Y., Ertopcu, K., Ozelmas, I., “The Predictors of
Retained Products of Conception Following First-trimester Pregnancy Termination with
Manual Vacuum Aspiration”, Eur J Contracept Reprod Health Care, 11 (2): 98-103
(2006).
L17.1. Müngen, E., Dundar, O., Babacan, A., “Postabortion Doppler Evaluation of
the Uterus; Incidence and Causes of Myometrial Hypervascularity”, JUM, 28 (8):
1053-1060 (2009).
L17.2. Kara, F., Dogan, NU., Bati, S, Demir, S., Durduran, Y., Celik, C., “Early
surgical abortion: Safe and effective”, The European Journal of Contraception and
Reproductive Health Care, 18 (2): 120-126 (2013).
L17.3. Russo, JA., DePiñeres, T., Gil, L., “Controversies in family planning:
retained products of conception”, Contraception, 86 (5): 438-42 (2012).
L17.4. Maged, A., Gaffar, H., Mostafa, W., “Role of transvaginal ultrasound in
detection of retained products of conception after abortion”, Saudi J Health Sci, 1
(3): 151-155 (2012).
L17.5. Mentula, M., “Second trimester medical termination of pregnancy:
procedure,
immediate
complications
and
the
risk
of
repeat
termination”,
University of Helsinki, Faculty of Medicine, Institute of Clinical Medicine, Doctoral
Thesis (2012).
L18. (A14). Yildirim, Y., M. Inal, Tinar S., “Necrotizing Fasciitis after Abdominal
Hysterectomy: A Report on Five Cases”, Arch Gynecol Obstet, 273 (2): 126-128 (2005).
L18.1. Bharathan, R., Hanson, M., “Diagnostic laparoscopy complicated by group
A streptococcal necrotizing fasciitis”, J Minim Invasive Gynecol, 17 (1): 121-123
(2010).
L18.2. Faro, S., Faro, JP., “Necrotizing Soft-tissue Infections in Obstetric and
Gynecologic Patients”, Clinical Obstetrics & Gynecology, 55 (4): 875–887 (2012).
L18.3. Chifu, C., Diaconu, C., Andriescu, L., Palaghiu, R., Grigoras, O., Damian,
N., “Rare complication of colostomy”, Chirurgia, 101 (4): 433-436 (2007).
50
L18.4. Kurdoğlu, Z., Akşin, S., Kolusarı, A., “Abdominal histerektomi sonrası
insizyon bölgesinde nekrotizan fasit: olgu sunumu”, Anatol J Clin Investig, 5 (4):
186-188 (2011).
L18.5. Campa, MF., Juliana Cano-Mejia, J., Madenjian, R., "A Review of the
Pathogenesis of Necrotizing Fasciitis by Group A Streptococci", The Spectra, The
Virginia Engineering and Science Research Journal, (2011).
L19. (A10). Sehirali, S., M.M. Inal, Ozsezgin, S., Sanci, M., Atli, O., Nayki, C., Yildirim,
Y., Tinar S., “A Randomized Prospective Study of Comparison of Reservoir Ports versus
Conventional Vascular Access in Advanced-Stage Ovarian Carcinoma Cases Treated with
Chemotherapy”, Int J Gynecol Cancer, 15 (2): 228-232 (2005).
L19.1. Goossens, GA., Stas, M., Jérôme, M., Moons, P., “Systematic review:
malfunction of totally implantable venous access devices in cancer patients,”
Supportive Care in Cancer, 19 (7): 883-898 (2011).
L19.2. Cahalane, AK., Rassnick, KM., Flanders, JA., “Use of vascular access ports
in femoral veins of dogs and cats with cancer”, Journal of the American Veterinary
Medical Association, 231 (9): 1354-1360 (2007).
L19.3. Camp-Sorrell, D., “Accessing and Deaccessing Ports: Where Is the
Evidence?”, Clinical Journal of Oncology Nursing, 13 (5): 587-590 (2009).
L19.4. David, L., Béatrice, L., Justine, GD., Véronique, LG., Chantal, D., et al.
“Clinical Outcome After a Totally Implantable Venous Access Port-Related
Infection in Cancer Patients: A Prospective Study and Review of the Literature”,
Medicine, 91 (6): 309–318 (2012).
L19.5. Fernández-de-Maya, J., Richart-Martínez, M., “Variability in management
of implantable ports in oncology outpatients”, European Journal of Oncology
Nursing, 17 (6): 835–840 (2013).
51
L20. (A5). M.M. Inal, Ertopcu, K., Arici, A., Ozelmas, I., “The Effect of Oral versus
Vaginal Misoprostol on Cervical Dilatation in First-trimester Abortion: A Double-blind,
Randomized Study”, Eur J Contracept Reprod Health Care, 8 (4): 197-202 (2003).
L20.1. Hussain, A., Ahsan, F., “The vagina as a route for systemic drug delivery”,
Journal of Controlled Release, 103 (2): 301–313 (2005).
L20.2. Yan, Z., Kaiyu, T., Lin T., et al. “Effectiveness and Safety of Oral
Misoprostol for Cervical Ripening before Artificial Abortion of First-trimester
Pregnancy:A Systematic Review”, Journal of practical Obstetrics and Gynecology,
22 (12): (2006).
L20.3. Inal, MM., Yildirim, Y., Ertopcu, K., Ozelmas, I., “The predictors of retained
products of conception following first-trimester pregnancy termination with
manual
vacuum
aspiration”,
The
European
Journal
of
Contraception
and
Reproductive Health Care, 11 (2): 98-103 (2006).
L20.4. Krishna, SV., Ashok, V., Chatterjee, A., “A Review on Vaginal Drug
Delivery Systems”, IJBPAS, 1 (2): 152-167 (2012).
L20.5. Chang-ping, G., Yan, Z., Jing, F., You-ping, L., et al. “Effectiveness and
Safety of Vaginal and Sublinguinal Misoprostol for Cervical Ripening before
Artificial Abortion of First-Trimester Pregnancy: A Systematic Review”, The Journal
of Evidence Based Medicine, 7 (4): (2007).
L21. (A11). Ertopcu, K., M.M. Inal, Ozelmas, I., “Demographic Analysis of PostAbortive and Interval-Administered Hormonal Contraceptive Methods”, Eur J Contracept
Reprod Health Care, 10 (1): 1-5 (2005).
L21.1. Mittal, S., “Contraception after medical abortion”, Contraception, 74 (1):
56–60 (2006).
L21.2. Palanivelu, LM., Oswal, A., “Contraceptive practices in women with repeat
termination of pregnancies”, Journal of Obstetrics & Gynaecology, 27 (8): 832834 (2007).
L21.3. Prata, N., Bell, S., Holston, M., Gerdts, C., Melkamu, Y., “Factors
Associated with Choice of Post-Abortion Contraception in Addis Ababa, Ethiopia”,
African Journal of Reproductive Health, 15 (3): (2011).
52
L22.(A7). Yildirim, Y., M.M. Inal, Sanci, M., Sentas, A., Hanhan, M., “Uterine
Sarcomas: A 10 Year Experience and A Review of the Literature”, Women’s Oncology
Review, 4 (1): 7-12 (2004).
L22.1. Gottwald, L., Gora, E., Korczynski, J., Piekarski, JH., Morawiec, Z., et al.
“Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer
and gastrointestinal stromal tumor”, Journal of Obstetrics and Gynaecology
Research, 34 (4): 721–725 (2008).
L22.2. Gómez, ASM., Blanco, RG., Loza, RA., Martínez, AS., Lara, HJMM., Zuani,
JGZ., “Uterine Sarcoma: Case Report”, Ginecol Obstet Mex, 80 (3): 224-227
(2012).
L22.3. Ertas, IE., Doğan, A., Özdemir, A., Solmaz, U., et al. “The effect of
adjuvant treatment modalities on survival outcomes in cytoreductive surgery
performed patients with advanced stage uterine sarcomas”, Ege Journal of
Medicine, 52 (4): 179-184 (2013).
L23. (A6). Tinar, S., Sehirali, S., M.M. Inal, Yildirim, Y., Celik, E., Yigit, S.,
“Adenosarcoma of the Uterus: A Case Report”, MedGenMed (electronic resource):
Medscape General Medicine, 6 (1): 51 (2004).
L23.1. Rita Sakr, R., Marzouk, P., Bricou, A., Fabien Demaria, F., Annie Cortez,
A., Benifla, JL., “Uterine adenosarcoma associated to lymphovascular emboli: a
case report”, Cases Journal, 2 (7515): 1-3 (2009).
M. Ulusal kitap yazarlığı veya Ulusal kitaplarda bölüm yazarlığı:
M1. Avcı, ME., M.M. İnal., “Gebelik ve Travma”, Temel Kadın Hastalıkları ve Doğum
Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım,
s353-362 (2008).
M2. Avcı ME., M.M. İnal., “Sıvı-Elektrolit Dengesi”, Temel Kadın Hastalıkları ve Doğum
Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım,
s769-777 (2008).
53
M3. Avcı ME., M.M. İnal., “Premenstrüel Sendrom”, Temel Kadın Hastalıkları ve Doğum
Bilgisi, ed. Ayhan, A., Durukan, T., Günalp, S., et al, Güneş Tıp Kitabevleri; 2. Basım,
s851-863 (2008).
N. Ulusal Bilimsel Toplantılara Katılım:
N1. Menapoz ve Hormon Replasman Tedavisi 4. Uludağ Sempozyumu, 4-7 Mart 1999,
Bursa.
N2. 1. Ulusal Aile Planlaması Kongresi, 14-17 Nisan 1999, Ankara.
N3. 7. Ulusal Perinatoloji Kongresi, 2- 6 Mayıs 1999, Antalya.
N4. 1st Reproductive Medicine 2000, June 7-10, 2000, Istanbul.
N5. 1st International Congress on the Menopause and the 4th National Congress, 17-21
Mayıs 2000, Antalya.
N6. 21st century Reproductive Medicine and Endoscopic Surgery Congress, 14-17
September 2000, Kuşadası, Aydın.
N7. Türk-Alman Jinekoloji Derneği 4. Kongresi, 30 Mayıs- 3 Haziran 2001, Antalya.
N8. 8. Ulusal Jinekolojik Onkoloji Kongresi, 1-5 Mayıs 2002, Antalya.
N9. 1. Ege Jinekolojik Endoskopik Cerrahi Sempozyumu, 13-14 Aralık 2002, İzmir.
N10. 3. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, 20-23 Nisan 2003,
Ankara.
N11. Güncel İnfertilite ve Yardımcı Üreme Teknikleri Sempozyumu, 24-27 Nisan 2003,
İzmir.
N12. 5. Türk-Alman Jinekoloji Derneği ve 2.Reproductive Medicine Tartışmalı Konular ve
Çözümler Ortak Kongresi, 16-20 Mayıs 2003, Antalya.
N13. 4. Ulusal Jinekoloji ve Obstetrik Kongresi, 20-25 Nisan 2004, Antalya.
N14. 9. Ulusal Jinekolojik Onkoloji Kongresi, 4-8 Mayıs 2004, Antalya.
N15. 2. Ege Jinekolojik Endoskopi Sempozyumu ve Workshop, 10-12 Mart 2005, İzmir.
54
N16. 4. Uluslararası Üreme Sağlığı ve Aile Planlaması Kongresi, 20-23 Nisan 2005,
Ankara.
N17. 10. Ulusal Jinekolojik Onkoloji Kongresi, 19-23 Nisan 2006, Antalya.
N18. 5. Ulusal Jinekoloji ve Obstetrik Kongresi, 16-21 Mayıs 2006, Antalya.
N19. Doppler USG ve Obstetri’de Uygulamaları Sempozyumu, 1 Aralık 2006, İzmir.
N20. 6. Ulusal Jinekoloji ve Obstetri Kongresi, 14-19 Mayıs 2008, Antalya.
N21. 10. Ulusal Jinekoloji ve Obstetri Kongresi, 09-13 Mayıs 2012, Antalya.
N22. 5. Ulusal Üreme Endokrinolojisi ve İnfertilite Kongresi, 27-30 Eylül 2012, İzmir.
N23. 13. Ulusal Jinekolojik Onkoloji Kongresi, 07-11 Kasım 2012, Antalya.
O. Eğitim kursu katılımları:
O1. Endokrin Hastalıklarda Laboratuar Değerlendirme Kursu, 30 Nisan – 2 Mayıs 2001,
İzmir.
O2. Neonatal Resüsitasyon Kursu, 25-27 Nisan 2001, İzmir.
O3. Fetal Anomaly Scanning Course (ISUOG Outreach Programme), 3 May 1999,
Antalya.
55